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Abstract
Three series (6, 13, and 14) of new diarylaniline (DAAN) analogues were designed, synthesized, 
and evaluated for anti-HIV potency, especially against the E138K viral strain with a major 
mutation conferring resistance to the new-generation non-nucleoside reverse transcriptase inhibitor 
drug rilpivirine (1b). Promising new compounds were then assessed for physicochemical and 
associated pharmaceutical properties, including aqueous solubility, log P value, and metabolic 
stability, as well as predicted lipophilic parameters of ligand efficiency, ligand lipophilic 
efficiency, and ligand efficiency-dependent lipophilicity indices, which are associated with ADME 
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property profiles. Compounds 6a, 14c, and 14d showed high potency against the 1b-resistant 
E138K mutated viral strain as well as good balance between anti-HIV-1 activity and desirable 
druglike properties. From the perspective of optimizing future NNRTI compounds as clinical trial 
candidates, computational modeling results provided valuable information about how the R1 group 
might provide greater efficacy against the E138K mutant.
Graphical abstract
INTRODUCTION
Because of their high potency and low toxicity, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) are used as key drugs in highly active antiretroviral therapy (HAART)1 
for the treatment of HIV infection and AIDS. However, resistance to some drugs, especially 
to the early NNRTI drugs nevirapine, delavirdine, and efavirenz, has occurred as a result of 
rapidly developing mutations of the viral NNRTI binding site. To address this major 
problem, two next-generation NNRTI drugs, etravirine (TMC125, 1a)2 and rilpivirine 
(TMC278, 1b)3 (Figure 1), were successfully developed and approved by the U.S. Food and 
Drug Administration (FDA) in 2008 and 2011, respectively. Compounds 1a and 1b belong 
to the same diarylpyrimidine (DAPY) family, possess extremely high potency against the 
wild type and a broad spectrum of mutated NNRTI strains resistant to early NNRTI drugs,4 
and also present a higher genetic barrier against HIV-1 resistance,5, 6 most likely resulting 
from their molecular flexibility. However, because of the high mutation rate of HIV-1 RT 
and the lack of intrinsic exonucleolytic proofreading activity, new resistance profiles 
associated with 1a and 1b are also being observed in patients.7, 8 These viral mutations are 
distinct from each other9 as well as distinct from those seen with the early NNRTI drugs. 
Consequently, novel NNRTI drugs with high potency and different molecular scaffolds are 
still needed to overcome new drug resistance regimes associated with the new-generation 
NNRTI anti-HIV drugs 1a and 1b and to provide more efficacious therapies and treatment 
options.
In our prior studies of novel HIV-1 NNRTI agents, we discovered two series of extremely 
potent anti-HIV NNRTI agents, diarylanilines (DAANs, 2)10 and diarylpyridiamines 
(DAPAs, 3),11, 12 as shown in Figure 2. The new chemo-type scaffolds have topologic shape 
and molecular flexibility similar to those of new-generation NNRTI drugs 1a and 1b. The 
initial leads 2a and 3a exhibited high anti-HIV potency against wild-type HIV-1 replication 
with low to subnanomolar EC50 values of 3.0 and 0.71 nM, respectively, comparable to 
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those of 1a (EC50 = 1.5 nM) and 1b (EC50 = 0.51 nM) in the same assays.10, 12 However, 
very low bioavailability (F% < 3) in rats impeded their further development. Subsequently, 
multiple structural modifications were introduced to identify structure-activity relationship 
(SAR) and structure-property relationship (SPR) correlations for DAANs and DAPAs as 
new HIV-1 NNRTI agents. The subsequent leads 2b13 (DAAN) and 3b14 (DAPA) exhibited 
not only extremely high potency against both wild-type (EC50 values of 0.39 and 3.25 nM, 
respectively) and drug-resistant (EC50 values of 1.8–3.4 and 3.5–6.9 nM, respectively) viral 
replication but also improved druglike properties. Lead 2b had a desirable log P value of 
3.68 and a high water solubility of 90 µg/mL at pH 2.0, but its higher metabolism and 
instability in various solvents prompted continued structural optimization. On the other 
hand, lead 3b had high antiresistance potency, with especially low resistance fold changes 
(FC = 1.1–2.1) for K101E and E138K viral strains resistant to new drugs 1a and 1b, 
respectively, compared with that for wild-type NL4-3 virus. This interesting advantage 
provided the opportunity to explore compounds capable of overcoming the drug resistance 
associated with 1a and 1b. Therefore, current optimization efforts have been aimed at 
discovering new DAANs as potential drug candidates with high antiresistance potency and 
good balance between antiviral activity and multiple druglike properties. Guided by the prior 
SAR results, we designed and synthesized three new series (6, 13, and 14) of DAAN 
derivatives and evaluated them against HIV-1 wild-type virus and the E138K variant, which 
contains the most frequent mutation conferring resistance to 1b,15 as well as other resistant 
viral strains. Meanwhile, essential druglike properties and parameters were also assessed and 
predicted. Herein, we reported our new results and further discussion of SAR and SPR 
correlations for DAANs and DAPAs.
DESIGN
As demonstrated in Figure 2, while potent NNRTI DAANs and DAPAs differ by having a 
benzene and pyridine ring, respectively, as the central ring (B-ring), they also have three of 
the same known pharmacophores, a p-cyanoaniline moiety (A-ring), the NH2 group on the 
central B-ring ortho to the A-ring, and a 2,4,6-trisubstituted phenoxy ring (C-ring). With 
good molecular flexibility and a topologic shape similar to that of 1b, these compounds can 
adjust their binding conformations to fit the binding site within both wild-type and mutated 
NNRTI binding pockets. Previous SARs revealed that a linear hydrophobic para-R2 
substituent on the C-ring is favorable for potency with the following rank order: cyanoethyl 
> cyanovinyl > cyano. On the other hand, the R1 substituent on the central B-ring and X 
substituents on the C-ring can be modified to improve molecular properties without a loss of 
potency. Importantly, on the basis of prior molecular docking results,12 the R1 substituent on 
the B-ring is outside of the main NNRTI binding pocket and close to susceptible amino acid 
E138 on the p51 subdomain of the HIV-1 reverse transcriptase. Thus, modification of this R1 
group could provide an interaction between it and the mutated K138, or other preserved 
amino acid(s) nearby or on the interface between p66 and p51 subdomains, to possibly 
overcome mutated E138K resistance. Therefore, in the newly designed DAAN analogues (6, 
13, and 14 series), continued optimizations addressed modifications of the R1 and X sub-
stituents, while the p-cyanoethyl substituent (R2) on the phenoxy ring (C-ring)16 and p-
cyanoaniline (A-ring) were maintained (see the formula in Figure 2). Because the R1 
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substituent is also associated with molecular physicochemical properties, the current 
optimization strategy should result in a balance between antiviral potency and multiple drug-
likeness profiles, which are criteria for advancing a potential drug candidate to the clinic. 
Additionally, a suitable R1 side chain oriented toward the interface between the HIV-1 RT 
p66 and p51 subdomains could overcome the drug resistance of E138 K. The series 6 
DAAN compounds incorporated various R1 groups with different shapes, volumes, and 
flexibilities, including amides (6a–d), alkylamines (6e–g), esters (6h,i), carbamates (6j), 
alkoxyethers (6k,m), and halogens (6n,p), to investigate the effects of these groups on 
potency, antiresistance, and druglike properties. Hetero atoms, such as O or N, in certain R1 
substituents could provide additional interactions with the amino acids on interfaces between 
p66 and p51 subdomains of the RT enzyme via H-bonds or other forces to increase potency 
against the E138K mutation and improve molecular physicochemical properties, as well as 
related druglike properties. In addition, the X groups on the C-ring were modified for 
antiresistance and metabolic stability,17, 18 resulting in two small sets of new DAANs, the 
dimethoxy-13 series and the methoxy/bromo-14 series, with either an N-methyl 
carboxamide or a methyl carboxylate as the R1 substituent. These limited structural 
optimizations should provide a better understanding of how structure affects potency against 
HIV-1 wild-type and resistant viral strains, especially for the E138K mutation, as well as 
other drug properties, with the aim of discovering and developing potential new NNRTI drug 
candidates.
Chemistry
As shown in Scheme 1, new compounds 6a–c and 6h–n were synthesized from 2m, a prior 
intermediate in the synthesis of DAANs.13 The 4-ester group on the central phenyl ring in 
2m was either hydrolyzed under basic conditions or reduced with LiBH4 to the 
corresponding carboxylic acid (4a) or hydroxymethyl (4b) derivative, respectively. 
Compound 4a was then treated with SOCl2 followed by amidation with different amines in 
THF at 0 °C to produce the 4-amido compounds 5a–c. On the other hand, treating 4b with 
2,4,6-trichloro[1,3,5]triazine (TCT)19 produced the chloromethyl product 4c, which was 
reacted immediately with dimethylamine, cyclopropanamine, and 1-methylpiperazine to 
yield the corresponding 4-alkylaminomethyl compounds 5e–g, respectively. Alternatively, 
compound 4b was reacted with acetic anhydride, cyclopropanecarbonyl choloride, and 
methylcarbamic chloride to yield the corresponding reversed ester compounds 5h and 5i and 
carbamate compound 5j, respectively. Moreover, 4b was converted to methoxymethyl 
compound 5k by reaction with methanol in the presence of BiCl3 at room temperature. Next, 
the nitro group and the double bond of the p-cyanovinyl in intermediates 5a–c and 5e–k 
were reduced simultaneously by catalytic hydrogenation with Pd-C (10%) in anhydrous 
ethanol or EtOAc to produce the new DAAN compounds 6a–c and 6e–k, respectively.
In addition, a new convergent synthetic route was explored to efficiently synthesize 
additional p-cyanoethylphenoxy-DAANs (Schemes 2 and 3). The C-ring building block 4-
cyanoethyl-2,6- dimethyl phenol (9a) was prepared from commercial reagent 7a in three 
steps: benzoylation of the phenol, Wittig reaction of the aldehyde group with diethyl 
cyanomethylphosphonate, and deprotection by catalytic hydrogenation. Because an 
electrondonating p-cyanoethyl group was present, the coupling of 9a with10a, an 
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intermediate synthesized and identified previously,10, 13 was performed easily to produce 
2,4-diaryl nitrobenzene 11a in a high yield of 94%. By conversions similar to those shown in 
Scheme 1, 11a was converted to the carboxylic acid (11b) and hydroxymethyl (11c) 
compounds. Compound 11b was converted to the N-substituted carbamoyl product 11d, 
while 11c was modified successively to the chloromethyl (11e) and ethoxymethyl (11m) 
nitrodiarylanilines. By Curtius rearrangement,20 the 4-carboxylic acid group of 11b was 
converted to a 4-amino moiety in 11f, which underwent diazonization followed by reaction 
with cuprous bromide to produce the desired 4-bromo product 11n and the nonbrominated 
byproduct 11o. Alternatively, coupling of 9a with 10b was performed under microwave 
irradiation in DMF in the presence of K2CO3 at 110 °C for 10 min to produce 4-chloro 
compound 11p (R1 = Cl). Finally, nitro compounds 11d and 11m were reduced conveniently 
by catalytic hydrogenation to corresponding amino products 6d and 6m, respectively. 
However, halogenated nitro compounds 11n–p were reduced by using the mild reductive 
reagent Fe/NH4Cl to obtain corresponding amino compounds 6n–p, respectively. This 
reaction showed a clear color change from yellow to colorless to identify the reaction’s end.
With the same method that was used for the preparation of 9a, building blocks 4-
cyanoethyl-2,6-dimethoxy phenol (9b) and 2-bromo-4-cyanoethyl-6-methoxyphenol (9c) 
were synthesized from commercially available 7b and 7c, respectively. As described in 
Scheme 4, compounds 13 (X = OMe) and 14 (X = OMe/Br) were synthesized from 
compound 10a by coupling with 9b or 9c to produce corresponding esters 13a and 14a 
followed by amidation with methylamine to yield 13b and 14b, respectively. Similar to 
previous reductions, the 4-nitro in compounds 13a and 13b was reduced by catalytic 
hydrogenation, whereas halogenated compounds 14a and 14b were reduced with Fe/NH4Cl 
to generate corresponding DAANs 13c, 13d, 14c, and 14d, respectively. All new target 
compounds in the 6, 13, and 14 series were identified by 1H NMR and mass spectrometry 
data.
RESULTS AND DISCUSSION
Antiviral Activity and SAR Analysis
All new DAAN compounds (6, 13, and 14 series) were evaluated against wild-type HIV-1 
(NL4-3 and IIIB) and resistant viral strain (E138K, A17, and K101E) replication in TZM-bl 
(NL4-3 and E138K) and MT-2 (IIIB) cell lines, respectively. Their anti-HIV potency (EC50, 
as measured by a luciferase gene expression assay29) and cytotoxicity (CC50) as well as 
selective index (SI) data are summarized in Table 1. As expected, with the exception of 6d 
and 6g, most of the 6 series compounds with various R1 substituents exhibited extremely 
high potency against wild-type HIV-1 NL4-3 replication in TZM-bl cell lines with low 
nanomolar EC50 values ranging from 0.53 to 16.0 nM. These results were consistent with 
our previous findings, which indicated that the R1 group can be modified without loss of 
anti-HIV potency. However, the presence of very bulky R1 groups, e.g., 4-(N-
isopropyl)carbamoyl in 6d and 4-(N-methylpiperazine)-carbamoyl in 6g, impeded molecular 
antiviral potency, resulting in EC50 values of 72 and 115 nM, respectively. We supposed that 
steric conflict between the bulky R1 groups and the viral amino acid residues within a 
limited space between the p51 and p66 domains might affect intermolecular affinity and 
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binding, leading to reduced potency. Interestingly, the three most potent compounds, 6c 
(EC50 = 2.00 nM), 6f (EC50 = 0.53 nM), and 6i (EC50 = 1.63 nM), all contain a cyclopropyl 
moiety at the end of their R1 side chains; this moiety might have a suitable shape and 
volume to insert into a cleft between the p66 and p51 subdomains, thereby increasing 
molecular affinity. When the two X groups on the C-ring were changed, the dimethoxy-
DAANs [13c (R = COOCH3) and 13d (R = CONHCH3)] were at least 20-fold less potent 
than the corresponding bromo/ methoxy-DAANs (14c and 14d). Indeed, compounds 14c 
and 14d exhibited similar high potency (EC50 values of 5.19 and 5.58 nM, respectively) 
against wild-type NL4-3 virus replication and were almost as potent as the prior 
corresponding dimethyl-DAANs 2c (EC50 = 4.32 nM) and 2d (EC50 = 2.73 nM).13 
Therefore, molecular potency could be maintained by replacing the two methyl groups (X) 
on the C-ring with methoxy and bromo groups, but not with two methoxy groups. Thus, 
appropriate X groups are needed to achieve a favorable binding conformation of the C-ring 
moiety.
The active DAANs described above (6, 13, and 14 series) were also tested in the MT-2 cell 
line for inhibition of wild-type HIV-1 IIIB, as well as the multiple-resistant A17 viral strain, 
replication, and cytotoxicity. The EC50 values against two wild-type viruses (NL4-3 and 
IIIB) in different cellular assays showed some fluctuation, but similar potency and activity 
patterns were observed as shown in Table 1. Meanwhile, the low cytotoxicity (CC50 > 10 
µM) of the compounds resulted in extremely high selective index values ranging from 103 to 
105 (Table 1).
To evaluate our hypothesis concerning a possible link between the R1 substituent of a 
compound and its effectiveness against NNRTI-resistant virus, active DAAN compounds 
were tested against the E138K mutated viral strain, which has a major mutation conferring 
resistance to 1b, and the data are summarized in Table 1. Comparison of the results in the 
wild-type NL4-3 and drug-resistant E138K assays identified the most promising compounds 
as 6a, 6b, 14c, and 14d, as indicated by low resistance FCs of 1.9–2.2, which were much 
better than that of 1b (FC = 10), lower than those of the other new DAANs, and comparable 
with those of the prior 2c (FC = 1.7) and 2d (FC = 3.7) in the same assay. Notably, 6a, 6b, 
14c, and 14d, as well as 2c and 2d, all contain a carbonyl (C═O) group conjugated with the 
B-ring, regardless of whether the R1 group is an amide or ester. Thus, this carbonyl group 
might be important for inhibiting the E138K mutation, possibly because it could interact 
with the mutated K138 or nearby amino acid(s). Support for this postulate was found from 
the results for 6e, 6f, 6h, 6i, and 6k, in which the carbonyl group was changed to a 
methylene (−CH2-). Despite their high potency (EC50 = 0.53–3.3 nM) against wild-type 
NL4-3 virus, these compounds were much less potent against the E138K viral strain (EC50 > 
13.3–39 nM), leading to poorer resistance FC values of 9–48 compared with those of 6a, 6b, 
14c, and 14d. Thus, the presence of a conjugated carbonyl group in R1 on the B-ring is 
favorable against the E138K drug 1b resistance. In addition, representative compounds 6b, 
6p, and 2d, which had markedly improved drug-resistant profiles for the E138K mutant, 
were tested against another 1b–resistant viral strain, K101E. Again, improved drug-resistant 
profiles with low FC values of 3–4 were seen (Table 1). Moreover, eight active compounds 
(EC50 < 5 nM against IIIB) were further tested in the MT-2 cell line against the multi-NRTI-
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resistant A17 viral strain with mutants K103N and Y181C, the two major mutants from the 
first-generation NNRTI drugs. Except 6a and 6p, most of them showed high potency against 
the drug-resistant A17 viral strain with low nanomolar EC50 values and low FC values 
ranging from 0.9 to 14 [lower than that of 1b (FC = 18)] compared with wild-type IIIB virus 
in the same cellular assay, indicating that these compounds are also effective against 
multidrug resistance to the first-generation NNRTI drugs. Therefore, these results 
demonstrate that the R1 substituent is the key modification point for overcoming the 1b drug 
resistances and other multi-NRTI-resistant strains.
Molecular Modeling
A computational study was performed to demonstrate how the introduction or modification 
of a R1 substituent could contribute to overcoming E138K-induced drug resistance to 1b. If 
DAANs bind to both wild-type and mutant viruses such that the R1 group is oriented toward 
virus residue 138, then modification of its size, shape, and other properties could afford 
compounds that would interact with the mutant virus better than drug 1b, which could be 
measured analytically in terms of lowered FC values. Because of their high wild-type 
potency (single-digit nanomolar levels) with good FC values (2-fold), compounds 6a and 
14d were selected as representatives for the computational study. Again, the latter result is 
highly desirable for combating resistance in the E138K mutant virus. The compounds were 
docked computationally to both wild-type RT/1b [Protein Data Bank (PDB) entry 3MEC]21 
and mutated E138K RT/nevirapine (PDB entry 2HNY)22 complex crystal structures. For 
comparison, drug 1b was also docked to both the wild-type and mutant structures. The 
docking protocol is described in the computational section.
As shown in Figure 3, the docking poses of 6a (green) and 1b (gray) in both 3MEC (wild-
type) and 2HNY (E138K mutant) structures, respectively, displayed similar binding 
orientations with “U”-like conformational shapes and two characteristic hydrogen bonds 
formed with the key amino acid K101, consistent with prior results and literature reports on 
1b. In both cases, the R1 side chain of 6a pointed toward the domain space containing viral 
residue 138. The greater flexibility of K138 could make the mutant virus more tolerant than 
the wild-type virus toward various R1 side chain substitutions, as reflected by better FC 
values. Ten of the 14 docking cases were consistent with this observation. Moreover, as seen 
in the bottom half of Figure 3, the carbonyl group in the R1 substituent of 6a was oriented 
toward the amino group in the side chain of K138. Even though a clear interaction between 
the carbonyl in R1 and the amino group of K138 was not observed in the current models, 
additional H-bond(s) with a bridging water molecule could be formed to reach high affinity 
with the mutant target. The second representative compound 14d provided similar results, 
and its docking figures can be found in the Supporting Information. Therefore, the current 
modeling results supported our hypothesis that the R1 substituent is associated with the 
potency of the NNRTIs against viral mutants with resistance to NNRTIs and should, 
therefore, help in the further optimization of new drug candidates that can overcome the 
drug resistance to current NNRTI drugs.
On the other hand, to understand why a small structural change made a significant reduction 
in potency, we compared the docked models of both less active 13d (X = MeO/MeO) and 
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the corresponding active 14d (X = MeO/Br) into the wild-type structure (3MEC). As shown 
in Figure 4, the A-ring and B-ring in both molecules superimposed well, but the C-ring was 
tilted upward in 13d because of the steric effect of the bulkier methoxy group (outside) on 
this ring. We suppose that the C-ring in 13d is thus forced away from the Y181 or Y188 
residue, reducing the molecular affinity for the viral target and then decreasing the potency. 
However, the C-ring in 14d superimposed completely with that of active compound 6f [X = 
Me/Me (data not shown)], as the bromine atom in 14d is similar in size to the methyl (X) in 
series 6. Furthermore, less active 6g and active 6f were docked in the wild-type RT crystal 
structure (3MEC) following the same docking protocol. The bulkier group on R1 in 6g 
pushed more against E138, resulting in a minor shift in 6g’s binding mode compared with 
that of 6f (Figure in the Supporting Information). This shift may affect the critical 
interaction between the C-ring and residues W229, Y181, and Y188, thus providing support 
for our previous supposition for why 6g was less potent than 6f.
Druglike Properties and Parameters
Active DAANs 6a–c, 6e, 6f, 6h, 6i, 6k, 6n, 14c, and 14d (EC50 < 10 nM) were further 
assessed for certain physicochemical properties required for potential drug candidates to 
attain a critical balance between potency and druglike properties. According to methods 
described previously,13, 23 aqueous solubility at pH 7.4 and 2.0, log P values, and in vitro 
metabolic stability were measured, and the results are summarized in Table 2. Compounds 
6e and 6f with an alkylamine-R1 side chain displayed good molecular solubility at both pH 
2.0 (260 and 276 µg/mL, respectively) and pH 7.4 (23.4 and 13.6 µg/mL, respectively), 
typical physiological environments encountered by a drug in stomach and plasma, 
respectively. However, the carbamoyl-DAANs 6a, 6b, 6c, and 14d showed reasonable 
aqueous solubility (25.8–141 µg/mL) only at pH 2.0, regardless of whether X is Me/Me or 
MeO/Br. These results indicated that the increased molecular alkalescence afforded by the N 
atom in the R1 substituent of 6e and 6f led to improved molecular aqueous solubility, 
especially in an acidic medium. In contrast, the compounds with oxygen (O) or halogen 
atoms in the R1 side chain [see 6h and 6i (R1 = CH2OCOR′), 6k (R1 = CH2OMe), 6n (R1 = 
Br), and 14c (R1 = COOMe, and X = Br/OMe)] exhibited lower aqueous solubility ranging 
from 0.12 to 2.63 µg/mL at both pH 2.0 and 7.4. In total, the current results indicated the 
following rank order of aqueous solubility based on R1 side chain: alkylamine > amide > 
ester and ether groups. Improved molecular aqueous solubility under acidic conditions 
should enhance oral drug absorbability in the stomach. Along with aqueous solubility, 
lipophilicity is another important druglike property related to molecular biological potency, 
as well as absorption, distribution, metabolism, and excretion (ADME) profiles and toxicity 
risk. As shown in Table 2, except for 6n (log P > 5), all of the active compounds tested had 
desirable log P values within a range of 2.51–3.69 at pH 7.4. Therefore, insertion of hetero 
atoms into the R1 substituent served as an effective strategy for decreasing lipophilicity, 
while maintaining high potency, improving aqueous solubility, and decreasing the high risk 
of unwanted pharmacology.
Most recently, concepts such as ligand efficiency (LE),24 ligand lipophilic efficiency 
(LLE),25 and ligand efficiency-dependent lipophilicity (LELP)26 have been proposed and are 
being applied increasingly in many medicinal chemistry programs to usefully direct 
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optimization away from highly lipophilic compounds. Defined as the difference between the 
negative logarithm of the measured potency (pEC50) and log P, the LLE value is a simple but 
important index combining in vitro potency and lipophilicity, whereas LELP correlates with 
ADME properties. Accordingly, lipophilic parameters of the active DAANs were calculated 
by using experimental EC50 and log P values with the formulas cited at the bottom of Table 
2. Fortunately, most compounds, including 6a, 6c, 6e, 6f, 6h, 6i, 6k, 14c, and 4d, met 
acceptable levels for all three ligand lipophilic efficiency indices (LE > 0.3, LLE > 5, LELP 
< 10),27 while the remaining compounds in Table 2 did not. The compounds with a low 
LELP value would most likely have the greatest chance of passing all ADME and safety 
criteria. Additionally, topological polar surface area (t-PSA) parameters of active 
compounds were calculated with ChemDraw Ultra 12.0 and met the criterion28 of <140 Å2. 
These property assessment results indicated the postulate that optimization of optimized R1 
and X substituents could satisfy the dual goals of maintaining high antiviral potency and 
improving druglike properties at the same time by adjusting molecular lipophilicity.
Furthermore, the metabolic stability of active compounds was evaluated in a human liver 
microsome (HLM) assay; 1b and propranolol were also tested for comparison. As shown in 
Table 2, 6h and 6i were metabolized quite quickly, maintaining only 3.0 and 4.18%, 
respectively, of the parent compound after incubation for 30 min, with short t1/2 values of 
10.2 and 11.7 min, respectively. It is likely that the benzyl ester in the R1 side chain of both 
compounds is easily metabolized by enzymatic catalysis. In contrast, the remaining tested 
compounds maintained >50% of the original compound after incubation for 30 min. Among 
them, compounds 6e and 6k showed greater metabolic stability than propranolol, a common 
reference compound with moderate metabolic stability. Compounds 6b, 14c, and 14d were 
less stable than propranolol but more stable than 1b (t1/2 = 116 min). Compounds 6a and 6f 
(t1/2 = 99 min) had stability similar to that of 1b. Compounds 6c and 6n (R1 = Br) (t1/2 
values of 63 and 50 min, respectively) were less stable than 1b. Notably, both bromo 
compounds 14c and 14d (X = Br/OMe) showed reasonable metabolic stability (t1/2 = 139 
min) in the HLM assay, indicating that the halogen Br is acceptable at the X position on the 
C-ring instead of a methyl group. We further postulate that series 14 might have improved 
drug absorption leading to better oral bioavailability, because the high electronegativity of 
the introduced bromo atom (Br) could the balance molecular aqueous solubility and 
lipophilicity.
CONCLUSIONS
Current structural modification studies of DAANs showed that optimization of the R1 and X 
substituent on the central phenyl ring (B-ring) and phenoxy ring (C-ring), respectively, could 
enhance, or maintain, high potency against wild-type and E138K mutant HIV-1 replication 
and improve molecular aqueous solubility, lipophilicity, and metabolic stability, thus 
reaching a good balance between high antiviral potency and multiple druglike properties. On 
this basis, compounds 6a, 14c, and 14d might be potential drug candidates for further 
development to address new drug resistance deficiencies. Current SAR study further 
revealed that (1) a carbonyl group in the R1 substituent conjugated with the central phenyl 
ring (B-ring) is necessary to combat drug resistance from the E138K mutant, (2) hetero 
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atoms (O, N, or Br) in the R1 substituent favor improved druglike ADME properties, (3) 
bulky R1 groups should be avoided, and (4) Br and OMe could replace the two original 
methyl groups in DAANs, but two methoxy groups (X) on the C-ring led to reduced 
potency, because a steric effect altered the favorable conformation of the C-ring. Most 
interestingly, we found that the introduced R1 side chain provided a possibility for 
overcoming the new drug resistance from E138K, a major HIV-1 viral mutant with 
resistance to the NNRTI drug 1b. For instance, compounds 6a, 6b, 14c, and 14d exhibited 
high potency against the wild type as well as E138K mutant (low nanomolar EC50 values) 
with low resistance FC values of 1.9–2.2, which are much lower than that of 1b (FC = 10). 
The modeling study with representative compounds 6a and 14d provided a rationale 
supporting the role of an optimized R1 group promoting greater efficacy against the E138K 
mutant, as well as demonstrating possible modification space between subdomains p66 and 
p51.
The structural design of these compounds was aimed at overcoming the E138K drug-
resistant variants, and the current results should help in the development of new NNRTI 
candidates that can overcome the major drug resistance conferred to the new-generation 
HIV-1 NNRTI drug 1b, as well as other RT-mutated drug resistances. It is likely that 
additional structural optimizations may be needed to obtain compounds effective against 
other less prevalent 1b–resistant variants. Nevertheless, the approach and the results of this 
study are expected to provide a useful blueprint for further structural optimization against 
the drug-resistant mutants.
EXPERIMENTAL SECTION
Chemistry
Melting points were measured with an RY-1 melting apparatus without correction. Proton 
nuclear magnetic resonance (1H NMR) spectra were measured on a JNM-ECA-400 (400 
MHz) spectrometer using tetramethylsilane (TMS) as the internal standard. The solvent used 
was CDCl3 unless otherwise indicated. Mass spectra were recorded on an ABI PerkinElmer 
Sciex API-150 mass spectrometer with electrospray ionization, and the relative intensity of 
each ion peak is presented as percent. The purities of target compounds were ≥95%, as 
measured by HPLC analyses, which were performed on an Agilent 1200 HPLC system with 
a UV detector and an Agilent Eclipse XDB-C18 column (150 mm × 4.6 mm, 5 µm), eluting 
with a mixture of solvents A and B under two conditions (acetonitrile/water or MeOH/
water). The microwave reactions were performed on a microwave reactor from Biotage, Inc. 
Thin-layer chromatography (TLC) and preparative TLC plates used silica gel GF254 (200–
300 mesh) purchased from Qingdao Haiyang Chemical Co. Medium-pressure column 
chromatography was performed using a CombiFlash companion purification system. All 
chemical reagents, NADPH, and solvents were obtained from Beijing Chemical Works or 
Sigma-Aldrich, Inc. Pooled human liver microsomes (lot no. 20150323H) (protein content 
of 20 mg/mL, 0.5 mL) were purchased from iPhase Biosciences Ltd. (Beijing, China). HLM 
assay data analysis was conducted on an LC-MS system with an ABI PerkinElmer Sciex 
API-3000 mass spectrometer with electrospray ionization.
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4-Carboxy-N1-(4′-cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-2-
nitroaniline (4a)—To a solution of N1-(4′-cyanophenyl)-5-(4″-cyanovinyl-2″,6″-
dimethylphenoxy)-4-methoxycarbonyl-2-nitroaniline (2m) (234 mg, 0.50 mmol) in a THF/
MeOH solvent (6:1, v/v) was added a few drops of aq NaOH (1 N), and the mixture was 
stirred at room temperature for 10 h. The mixture was poured into ice-water, and the pH was 
adjusted to 2 with aq HCl (2 N). The precipitated solid was collected, washed with water, 
and dried to afford 204 mg of 4a: 90% yield; yellow solid; mp 260–262 °C; 1H NMR 
(DMSO-d6) δ 2.06 (6H, s, 2 × CH3), 5.95 (1H, s, ArH-6), 6.44 (1H, d, J = 16.4 Hz, ═CH), 
7.22 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.47 (2H, s, ArH-3″,5″), 7.58 (1H, d, J = 16.4 Hz, 
CH═), 7.65 (2H, d, J = 8.8 Hz, ArH-3’,5’), 8.72 (1H, s, ArH-3), 9.79 (1H, s, NH), 13.21 
(1H, s, COOH); MS m/z (%) 453.3 (M - 1, 45), 409.0 (M - 44, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-
hydroxymethyl-2-nitroaniline (4b)—To a solution of 3 (234 mg, 0.50 mmol) in THF (5 
mL) was added LiBH4 (36 mg, 0.16 mmol) at 0 °C while the mixture was being stirred over 
30 min. After MeOH (13 drops) was added dropwise, the mixture was being stirred at room 
temperature for 1 h. The mixture was poured into ice-water, and the pH was adjusted to 2–3 
with aq HCl (5%). The solid crude product was filtered out and purified by CombiFlash 
column chromatography (gradient elution, EtOAc/CH2Cl2, 0 to 3%) to produce 200 mg of 
4b: 91% yield; yellow solid; mp 232–234 °C; 1H NMR δ 2.15 (6H, s, 2 × CH3), 4.89 (2H, s, 
CH2O), 5.85 (1H, d, J = 16.4 Hz, ═CH), 6.27 (1H, s, ArH-6), 7.05 (2H, d, J = 8.8 Hz, 
ArH-2′,6′), 7.21 (2H, s, ArH-3″,5″), 7.28 (1H, d, J = 16.4 Hz, CH═), 7.47 (2H, d, J = 8.8 
Hz, ArH-3’,5’), 8.41 (1H, s, ArH-3), 9.70 (1H, s, NH); MS m/z (%) 439.3 (M - 1, 100).
4-Chloromethyl-N1-(4′-cyanophenyl)-5-(4″-cyanovinyl-2″,6″-
dimethylphenoxy)-2-nitroaniline (4c)—2,4,6-Trichloro [ 1,3,5] triazine (TCT, 627 mg, 
3.41 mmol), soluble in DMF (4 mL), was stirred at room temperature for a few minutes, and 
a white solid appeared. The mixture was stirred for 1 – 2 h and added to a solution of 4b (1 
g, 2.27 mmol) in CH2Cl2 (15 mL) while the mixture was being stirred at room temperature 
for 4 h by TLC and was monitored until the reaction reached completion. The organic phase 
was washed with water, a saturated NaHCO3 solution, water, and brine, successively, and 
dried over anhydrous Na2SO4 overnight. After removal of solvent in vacuo, the crude 
product was purified by flash column chromatography (elution, CH2Cl2) to afford 800 mg of 
4c: 77% yield; yellow solid; mp 237–239 °C; 1H NMR δ 2.17 (6H, s, 2 × CH3), 4.77 (2H, s, 
CH2Cl), 5.85 (2H, d, J = 16.4 Hz, ═CH), 6.26 (1H, s, ArH-6), 7.06 (2H, d, J = 8.4 Hz, 
ArH-2′,6′), 7.22 (2H, s, ArH-3″,5″), 7.33 (1H, d, J = 16.4 Hz, CH═), 7.49 (2H, d, J = 8.4 
Hz, ArH-3’,5’), 8.41 (1H, s, ArH-3), 9.77 (1H, s, NH); MS m/z (%) 481.3 (M + Na, 100).
General Amidation Procedure for the Preparation of 5a–c
A solution of carboxylic acid compound 4a in SOCl2 (10 mL) was heated to reflux for 4 h 
and then poured into petroleum ether while the mixture was being stirred. The precipitated 
solid was collected by filter. The crude aryl chloride was redissolved in THF and an amine 
reagent (excess) added at 0 °C while the mixture was being stirred over 30 min. The solvent 
was removed under reduced pressure, and the residue was purified by flash column 
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chromatography (gradient elution, CH2Cl2/petroleum ether, 70 to 100%) to obtain the amide 
product.
4-Carboxy-N1 -(4′ -cyanophenyl)-5-(4″ -cyanovinyl-2″,6″ -dimethyl-
phenoxy)-2-nitroaniline (4a)—To a solution of N1-(4′-cyanophenyl)-5-(4″-
cyanovinyl-2″,6″-dimethylphenoxy)-4-methoxycarbonyl-2-nitroaniline (2m) (234 mg, 0.50 
mmol) in a THF/MeOH solvent (6:1, v/v) was added a few drops of aq NaOH (1 N), and the 
mixture was stirred at room temperature for 10 h. The mixture was poured into ice-water, 
and the pH was adjusted to 2 with aq HCl (2 N). The precipitated solid was collected, 
washed with water, and dried to afford 204 mg of 4a: 90% yield; yellow solid; mp 260–
262 °C; 1H NMR (DMSO-d6) δ 2.06 (6H, s, 2 × CH3), 5.95 (1H, s, ArH-6), 6.44 (1H, d, J = 
16.4 Hz, ═CH), 7.22 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.47 (2H, s, ArH-3″,5″), 7.58 (1H, d, 
J = 16.4 Hz, CH═), 7.65 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.72 (1H, s, ArH-3), 9.79 (1H, s, 
NH), 13.21 (1H, s, COOH); MS m/z (%) 453.3 (M - 1, 45), 409.0 (M - 44, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-
hydroxymethyl-2-nitroaniline (4b)—To a solution of 3 (234 mg, 0.50 mmol) in THF (5 
mL) was added LiBH4 (36 mg, 0.16 mmol) at 0 °C while the mixture was being stirred over 
30 min. After MeOH (13 drops) was added dropwise, the mixture was stirred at room 
temperature for 1 h. The mixture was poured into ice-water, and the pH was adjusted to 2–3 
with aq HCl (5%). The solid crude product was filtered out and purified by CombiFlash 
column chromatography (gradient elution, EtOAc/CH2Cl2, 0 to 3%) to produce 200 mg of 
4b: 91% yield; yellow solid; mp 232–234 °C; 1H NMR δ 2.15 (6H, s, 2 × CH3), 4.89 (2H, s, 
CH2O), 5.85 (1H, d, J = 16.4 Hz, ═CH), 6.27 (1H, s, ArH-6), 7.05 (2H, d, J = 8.8 Hz, 
ArH-2′,6′), 7.21 (2H, s, ArH-3″,5″), 7.28 (1H, d, J = 16.4 Hz, CH═), 7.47 (2H, d, J = 8.8 
Hz, ArH-3’,5’), 8.41 (1H, s, ArH-3), 9.70 (1H, s, NH); MS m/z (%) 439.3 (M - 1, 100).
4-Chloromethyl-N1-(4′-cyanophenyl)-5-(4″-cyanovinyl-2″,6″-
dimethylphenoxy)-2-nitroaniline (4c)—2,4,6-Trichloro[ 1,3,5]triazine (TCT, 627 mg, 
3.41 mmol), soluble in DMF (4 mL), was stirred at room temperature for a few minutes, and 
a white solid appeared. The mixture was stirred for 1–2 h and added to a solution of 4b (1 g, 
2.27 mmol) in CH2Cl2 (15 mL) while the mixture was being stirred at room temperature for 
4 h, monitored by TLC until the reaction reached completion. The organic phase was 
washed with water, a saturated NaHCO3 solution, water, and brine, successively, and dried 
over anhydrous Na2SO4 overnight. After removal of solvent in vacuo, the cure product was 
purified by flash column chromatography (elution, CH2Cl2) to afford 800 mg of 4c: 77% 
yield; yellow solid; mp 237–239 °C; 1H NMR δ 2.17 (6H, s, 2 × CH3), 4.77 (2H, s, CH2Cl), 
5.85 (2H, d, J = 16.4 Hz, ═CH), 6.26 (1H, s, ArH-6), 7.06 (2H, d, J = 8.4 Hz, ArH-2′,6′), 
7.22 (2H, s, ArH-3″,5″), 7.33 (1H, d, J = 16.4 Hz, CH═), 7.49 (2H, d, J = 8.4 Hz, ArH-3’,
5’), 8.41 (1H, s, ArH-3), 9.77 (1H, s, NH); MS m/z (%) 481.3 (M + Na, 100).
General Amidation Procedure for Preparation of 5a–c
A solution of carboxylic acid compound 4a in SOCl2 (10 mL) was heated to reflux for 4 h 
and then poured into petroleum ether while the mixture was being stirred. The precipitated 
solid was collected by filter. The crude aryl chloride was redissolved in THF and an amine 
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reagent added (excess) at 0 °C while the mixture was being stirred over 30 min. The solvent 
was removed under reduced pressure, and the residue was purified by flash column 
chromatography (gradient elution, CH2Cl2/petroleum ether, 70 to 100%) to obtain the amide 
product.
N1-(4″ -Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N,N-
dimethyl)carbamoyl-2-nitroaniline (5a)—Starting with 4a (300 mg, 0.66 mmol) and 
aqueous dimethylamine (33%, 5 drops) to afford 249 mg of 5a: 79% yield; mp 122.0–
124.0 °C; 1H NMR δ 2.20 (6H, s, 2 × CH3), 3.11 (3H, s, CH3N), 3.20 (3H, s, CH3N), 5.84 
(2H, d, J = 16.8 Hz, ═CH), 6.29 (1H, s, ArH-6), 7.08 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.20 
(2H, s, ArH-3″,5″), 7.31 (1H, d, J = 16.8 Hz, CH═), 7.50 (2H, d, J = 8.8 Hz, ArH-3’,5’), 
8.34 (1H, s, ArH-3), 9.75 (1H, s, NH); MS m/z (%) 482.4 (M + 1, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N-
ethyl)carbamoyl-2-nitroaniline (5b)—Starting with 4a (300 mg, 0.66 mmol), and 
aqueous ethylamine (65–67%, 3 drops) to afford 130 mg of 5b: 41% yield; yellow solid; mp 
208.3–210.0 °C; 1H NMR δ 1.26 (3H, t, J = 7.2 Hz, CH3), 2.17 (6H, s, 2 × CH3), 3.56 (2H, 
q, J = 7.2 Hz, CH2), 5.98 (2H, d, J = 16.4 Hz, ═CH), 6.28 (1H, s, ArH-6), 7.06 (2H, d, J = 
8.4 Hz, ArH-2′,6′), 7.27 (2H, s, ArH-3″,5″), 7.33 (1H, d, J = 16.4 Hz, CH═), 7.49 (2H, d, 
J = 8.4 Hz, ArH-3’,5’), 9.28 (1H, s, ArH-3), 9.77 (1H, s, NH); MS m/z (%) 482.3 (M + 1, 
100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N-
cyclopropyl)carbamoyl-2-nitroaniline (5c)—Starting with 4a (250 mg, 0.55 mmol) 
and cyclopropanamine (114 µL) to afford 170 mg of 5c: 63% yield; yellow solid; mp 234–
236 °C; 1H NMR δ 0.60 (2H, m, CH2), 0.91 (2H, m, CH2), 2.16 (6H, s, 2 × CH3), 2.98 (1H, 
m, NCH), 5.84 (2H, d, J = 16.4 Hz, ═CH), 6.27 (1H, s, ArH-6), 7.07 (2H, d, J = 8.4 Hz, 
ArH-2′,6′), 7.25 (2H, s, ArH-3″,5″), 7.35 (1H, d, J = 16.4 Hz, CH═), 7.49 (2H, d, J = 8.4 
Hz, ArH-3’,5’), 7.59 (1H, d, J = 7.2 Hz, CONH), 9.27 (1H, s, ArH-3), 9.77 (1H, s, NH); MS 
m/z (%) 494.3 (M + 1, 80), 437.3 (M - 56, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N,N-
dimethylamino)methyl-2-nitroaniline (5e)—A mixture of 4c (200 mg, 0.44 mmol) and 
aqueous dimethylamine (33%, 5 drops, excess) in THF (5 mL) was stirred at 0 °C for 2 h. 
The solvent was removed under reduced pressure to yield the crude product, which was 
purified by CombiFlash column chromatography (gradient elution, MeOH/CH2Cl2 0 to 3%) 
to afford 110 mg of 5e: 54% yield; yellow solid; mp 200–202 °C; 1H NMR δ 2.14 (6H, s, 2 
× CH3), 2.36 (6H, s, 2 × NCH3), 3.62 (2H, s, CH2N), 5.85 (1H, d, J = 16.8 Hz, ═CH), 6.27 
(1H, s, ArH-6), 7.03 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.21 (2H, s, ArH-3″,5″), 7.33 (1H, d, J 
= 16.8 Hz), 7.45 (2H, d, J = 8.8 Hz, ArH-3’,5’), 8.40 (1H, s, ArH-3), 9.63 (1H, s, NH); MS 
m/z (%) 423.2 (M - 44, 100), 468.4 (M + 1, 6.2).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N-
cyclopropylamino)methyl-2-nitroaniline (5f)—Preparation is the same as that of 5e. 
Starting with 4c (200 mg, 0.44 mmol) and cyclopropanamine (2 drops, excess) to produce 
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130 mg of 5f: 62% yield; yellow solid; mp 102–104 °C; 1H NMR δ 0.65 (4H, m, 2 × CH2), 
2.18 (6H, s, 2 × CH3), 2.40 (1H, m, CH), 4.22 (2H, s, CH2N), 5.85 (2H, d, J = 16.8 Hz, 
═CH), 6.27 (1H, s, ArH-6), 7.04 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.21 (2H, s, ArH-3″,5″), 
7.31 (2H, d, J = 16.8 Hz, CH═), 7.49 (2H, d, J = 8.8 Hz, ArH-3’,5’), 8.52 (1H, s, ArH-3), 
9.67 (1H, s, NH); MS m/z (%) 480.2 (M + 1, 4.8), 423.2 (M - 56, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-(N-
methylpiperazin-1-yl)methyl-2-nitroaniline (5g)—Preparation is the same as that of 
5e. Starting with 4c (70 mg, 0.15 mmol) and N-methylpiperazine (2 drops, excess) to afford 
58 mg of 5g: 73% yield; yellow solid; mp 194.2–195.3 °C; 1H NMR δ 2.14 (6H, s, 2 × 
CH3), 2.32 (3H, s, NCH3), 2.62 (8H, m, 4 × CH2), 3.68 (2H, s, CH2N), 5.84 (2H, d, J = 16.4 
Hz, ═CH), 6.26 (1H, s, ArH-6), 7.03 (2H, d, J = 8.4 Hz, ArH-2′,6′), 7.21 (2H, s, ArH-3″,
5″), 7.33 (1H, d, J = 16.4 Hz, CH═), 7.46 (2H, d, J = 8.4 Hz, ArH-3’,5’), 8.35 (1H, s, 
ArH-3), 9.64 (1H, s, NH); MS m/z (%) 423.3 (M - 99, 100), 523.3 (M + 1, 83).
4-Acetoxymethyl-N1 -(4′ -cyanophenyl)-5-(4″ -cyanovinyl-2″ ,6″ -
dimethylphenoxy)-2-nitroaniline (5h)—A mixture of 4b (93 mg, 0.21 mmol) and 
NaOH (30 mg, 0.75 mmol) in acetic anhydride (5 mL) was heated at 100 °C under 
microwave irradiation while the mixture was being stirred for 5 min. The mixture was 
poured into ice-water, and the precipitated yellow solid was collected and dried to yield 93 
mg of 5h: 95% yield; mp 229–231 °C; 1H NMR (DMSO-d6) δ 2.08 (9H, s, 2 × CH3 and 
CH3C═O), 5.26 (2H, s, CH2O), 6.04 (1H, s, ArH-6), 6.43 (1H, d, J = 16.8 Hz, ═CH), 7.15 
(2H, d, J = 8.4 Hz, ArH-2′,6′), 7.49 (2H, s, ArH-3″, 5″), 7.58 (1H, d, J = 16.8 Hz, CH═), 
7.61 (2H, d, J = 8.4 Hz, ArH-3’,5’), 8.33 (1H, s, ArH-3), 9.57 (1H, s, NH); MS m/z (%) 
483.4 (M + 1, 47.4), 505.2 (M + Na, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-
[(cyclopropane carbonyl)oxy]methyl 2-nitroaniline (5i)—A mixture of 4b (80 mg, 
0.18 mmol) and cyclopropanecarbonyl chloride (28.6 mg 0.27 mmol) in CH2Cl2 (5 mL) in 
the presence of pyridine (1 mL) was stirred at room temperature for 4 h, washed with 
aqueous HCl (5%), water, and brine, successively, and dried over MgSO4. After removal of 
solvent in vacuo, the residue was purified with PTLC [30:70:0.8 (v/v/v) cyclohexane/
CH2Cl2/acetone] to afford 74 mg of 5i: 80% yield; yellow solid; mp 190–191 °C; 1H NMR 
δ 0.94 (2H, m, CH2), 1.06 (2H, m, CH2), 1.70 (1H, m, CH), 2.15 (6H, s, 2 × CH3), 5.29 
(2H, s, CH2O), 5.85 (1H, d, J = 16.4 Hz, ═CH), 6.27 (1H, s, ArH-6), 7.06 (2H, d, J = 8.8 
Hz, ArH-2′,6′), 7.21 (2H, s, ArH-3″,5″), 7.33 (1H, d, J = 16.4 Hz, CH═), 7.48 (2H, d, J = 
8.8 Hz, ArH-3’,5’), 8.40 (1H, s, ArH-3), 9.74 (1H, s, NH); MS m/z (%) 533.5 (M + 23, 
100).
N1 (4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-[(N-
methylcarbamyl)oxy]methyl-2-nitroaniline (5j)—A mixture of 4b (150 mg, 0.34 
mmol) and methylcarbamic chloride (320 mg, 3.4 mmol) in pyridine (4.5 mL) was heated at 
120 °C under microwave irradiation while the mixture was being stirred for 30 min. The 
mixture was poured into ice-water, and the precipitated yellow solid was collected, washed 
with water, and dried to produce 157 mg of 5j: 93% yield; mp 210–211 °C; 1H NMR 
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(DMSO-d6) δ 2.14 (6H, s, 2 × CH3), 2.86 (3H, d, J = 4.8 Hz, NCH3), 5.29 (2H, s, ArCH2O), 
5.84 (1H, d, J = 16.8 Hz, CH═), 6.26 (1H, s, ArH-6), 7.05 (2H, d, J = 8.4 Hz, ArH-2′,6′), 
7.21 (2H, s, ArH-3″,5″), 7.32 (1H, d, J = 16.8 Hz, CH═), 7.47 (2H, d, J = 8.4 Hz, ArH-3’,
5’), 8.39 (1H, s, ArH-3), 9.71 (1H, s, NH); MS m/z (%) 514.9 (M + NH3, 100).
N1-(4′-Cyanophenyl)-5-(4″-cyanovinyl-2″,6″-dimethylphenoxy)-4-
methoxymethyl-2-nitroaniline (5k)—A mixture of BiCl3 (98 mg, 0.31 mmol) and 
MeOH (15 µL) in CCl4 (2 mL) was first stirred at rt for 20 min, followed by the addition of 
4b (110 mg, 0.25 mmol) in CH2Cl2 (5 mL). The mixture was stirred at room temperature for 
4 h. The solid was filtered out, and the filtrate was condensed under reduced pressure to gain 
crude product. It was purified by a flash column to produce 80 mg of pure 5k in 71% yield: 
yellow solid; mp 205–207 °C; 1H NMR δ 2.13 (6H, s, 2 × CH3), 3.52 (3H, s, OCH3), 4.62 
(2H, s, CH2O), 5.84 (1H, d, J = 16.8 Hz, ═CH), 6.26 (1H, s, ArH-6), 7.04 (2H, d, J = 8.8 
Hz, ArH-2′,6′), 7.20 (2H, s, ArH-3″,5″), 7.32 (1H, d, J = 16.8 Hz, CH═), 7.46 (2H, d, J = 
8.8 Hz, ArH-3’,5’), 8.39 (1H, s, ArH-3), 9.68 (1H, s, NH); MS m/z (%) 455.4 (M + 1, 100).
(E)-3-[4-(Benzyloxy)-3,5-dimethylphenyl]acrylonitrile (8a)—A mixture of 4-
hydroxy-3,5-dimethylbenzaldehyde (7a) (4 g, 26.7 mmol) and 1-(chloromethyl)benzene (4.1 
g, 32.0 mmol) in CH3CN (70 mL) in the presence of K2CO3 (7.4 g, 53.6 mmol, excess) was 
refluxed for 3 h. The solid K2CO3 was filtered out and washed with EtOAc several times. 
After removal of the organic solvent under reduced pressure, the residue was dissolved in 
THF (15 mL) and then slowly added to a mixture of (EtO)2P(O)CH2CN (7.1 g, 40 mmol) 
and t-BuOK (6 g, 53.6 mmol) in THF (10 mL) at 0 °C (ice-water bath) while the mixture 
was being stirred for 1 h. The mixture was then stirred for an additional 1 h and monitored 
by TLC until the reaction reached completion. The mixture was poured into ice-water, and 
the solid product was collected, washed with water to neutral, and dried to afford 6.45 g of 
8a (92% yield, white solid), which was ready for the next reaction directly without further 
purification.
(E)-3-[(4-Benzyloxy)-3,5-dimethoxyphenyl]acrylonitrile (8b)—The preparation was 
same as that of 8a. 4-Hydroxy-3,5-dimethoxybenzal-dehyde (7b, 2.41 g, 13.2 mmol) was 
first reacted with 1-(chloromethyl)-benzene (2.02 g, 15.9 mmol) in the presence of K2CO3 
(3.64 g, 26.4 mmol), following condensation with (EtO)2P(O)CH2CN (3.6 g, 20.4 mmol) to 
afford 1.4 g of 8b (36% yield, colorless oil), which was purified on a flash column 
chromatograph (gradient elution, EtOAc/ petroleum ether, 0 to 10%).
(E)-3-[4-(Benzyloxy)-3-bromo-5-methoxyphenyl]acrylonitrile (8c)—The 
preparation was the same as that of 8a. Starting with 3-bromo-4-hydroxy-5-
methoxybenzaldehyde (7c, 2.0 g, 8.66 mmol), 1-(chloromethyl)benzene (1.3 g, 10.4 mmol), 
and K2CO3 (2.4 g, 17.3 mmol), followed by condensation with (EtO)2P(O)CH2CN (1.1 g, 
8.9 mmol) in the presence of t-BuOK (1.0 g, 8.9 mmol) to afford 1.3 g of 8c, which was 
purified by a flash column chromatograph (gradient elution, EtOAc/petroleum ether, 0 to 
10%): 44% yield; white solid; mp 102.4–103.8 °C; 1H NMR δ 3.90 (3H, s, OMe), 5.08 (2H, 
s, ArCH2O), 5.79 (1H, d, J = 16.4 Hz, =CN), 6.89 (1H, s, ArH-5), 7.26 (1H, d, J = 16.4 Hz, 
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CH═), 7.27 (1H, s, ArH-2), 7.36 (3H, m, ArH-3′,4′,5′), 7.51 (2H, d, J = 7.6 Hz, ArH-2′,
6′); MS m/z (%) 365.9 (M + NH3, 100), 368.1 (80).
4-Cyanoethyl-2,6-dimethylphenol (9a)—The mixture of 8a (6.4 g, 24.3 mmol) in 
EtOH (50 mL) with H2 gas in the presence of excess Pd-C (10%) under a pressure of 30 psi 
was shaken for 2 h to yield 9a. After removal of Pd-C and solvent, the residue was purified 
by a flash column chromatograph (gradient elution, EtOAc/petroleum ether, 10 to 0%) to 
produce pure 3.89 g of 9a: 90% yield; white solid; mp 135.1 – 136.2 °C; 1H NMR 2.22 (6H, 
s, 2 × CH3), 2.56 (2H, t, J = 7.2 Hz, CH2CN), 2.82 (2H, t, J = 7.2 Hz, ArCH2), 6.83 (2H, s, 
ArH-2,6); MS m/z (%) 193.2 (M + NH3, 100).
4-Cyanoethyl-2,6-dimethoxyphenol (9b)—The preparation was the same as that of 9a. 
Starting with 8b (1.4 g, 4.7 mmol) in EtOAc (25 mL) to afford 920 mg of 9b in 94% yield, 
which was ready for the next reaction without further purification.
2-Bromo-4-cyanoethyl-6-methoxyphenol (9c)—The mixture of 8c (800 mg, 2.33 
mmol), Pd-C (5%, 50 mg), and ZnCl2 (300 mg, 2.20 mmol) in EtOAc (25 mL) with H2 gas 
under a pressure of 40 psi was shaken for 1.5 h to afford 500 mg of 9c: 74% yield; white 
solid; mp 85.2–87.1 °C; 1H NMR δ 2.60 (2H, d, J = 8.8 Hz, CH2CN), 2.87 (2H, t, J = 8.8 
Hz, ArCH2), 3.92 (1H, s, OCH3), 5.88 (1H, s, OH), 6.71 (1H, d, J = 1.2 Hz, ArH-6), 6.96 
(1H, d, J = 1.2 Hz, ArH-2); MS m/z (%) 273.2 (M + NH3, 100), 275.2 (100).
N1-(4-Cyanophenyl)-4,5-dichloro-2-nitroanilines (10b)—A mixture of 2,4,5-
trichloronitrobenzene (200 mg, 0.89 mmol), 4-aminobenzonitrile (126 mg, 1.08 mmol), and 
Cs2CO3 (580 mg, 1.77 mmol) in DMF (2 mL) was heated at 80 °C under microwave 
irradiation while the mixture was being stirred for 20 min. The mixture was poured into ice-
water and adjusted to pH 3; then precipitated solid product was collected by filtration and 
purified by a silica column with the CombiFlash chromatography system (gradient elution, 
CH2C2/ petroleum ether, 0 to 70%) to give 31 mg of 10b: 13% yield; orange solid; mp 180–
182 °C; 1H NMR δ 7.34 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.50 (1H, s, ArH-6), 7.32 (2H, d, J 
= 8.4 Hz, ArH-3′,5′), 8.36 (1H, s, ArH-3), 9.42 (1H, s, NH); MS m/z (%) 308.1 (M + 1, 
100), 310.3 (M + 3, 25).
5-[4″-(2-Cyanoethyl)-N1-(4′-cyanophenyl)-2″,6″-dimethylphe-noxy]-4-
methylcarbonyl-2-nitroaniline (11a)—A mixture of 10a (6 g, 18.1 mmol), which was 
prepared according to the method described in ref 11, and 9a (3.29 g, 19.0 mmol) in 60 mL 
of DMF in the presence of K2CO3 (4.50 g, 32.6 mmol) was heated at 110 °C while the 
mixture was being stirred for 4 h. The mixture was poured into ice-water, and precipitated 
yellow solid was collected to produce 8.0 g of pure 11a: 94% yield; mp 179–181 °C; 1H 
NMR δ 2.12 (6H, s, 2 × CH3), 2.61 (2H, t, J = 6.6 Hz, CH2CN), 2.87 (2H, t, J = 6.6 Hz, 
ArCH2), 3.96 (3H, s, OCH3), 6.26 (1H, s, ArH-6), 6.97 (2H, s, ArH-3″,5″), 7.07 (2H, d, J = 
8.8 Hz, ArH-2′,6′), 7.54 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.99 (1H, s, ArH-3), 9.85 (1H, s, 
NH); MS m/z (%) 439.2 (M - 31, 100), 471.2 (M + 1, 66).
4-Carboxy-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-
cyanophenyl)-2-nitroaniline (11b)—The preparation was the same as that of 4a. 
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Starting with 11a (2.5 g, 5.3 mmol) for 8 h to give 2.42 g of pure 11b: 99% yield; yellow 
solid; mp 220.0–222.0 °C; 1H NMR δ 2.13 (6H, s, 2 × CH3), 2.62 (2H, t, J = 7.2 Hz, 
CH2CN), 2.88 (2H, t, J = 7.2 Hz, ArCH2), 6.26 (1H, s, ArH-6), 7.00 (2H, s, ArH-3″,5″), 
7.10 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.70 (2H, d, J = 8.8 Hz, ArH-3′,5′), 9.17 (1H, s, 
ArH-3), 9.90 (1H, s, NH); MS m/z (%) 479.1 (M + Na, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
hydroxymethyl-2-nitroaniline (11c)—The preparation was the same as that of 4b. 
Starting with 11a (500 mg, 1.06 mmol) with LiBH4 (70 mg, 3.18 mmoL) in THF (15 mL) 
containing MeOH (13 drops) at 0 °C for 6 h to afford 400 mg of 11c: yellow solid; 85% 
yield; mp 152–154 °C; 1H NMR δ 2.12 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 
2.88 (2H, t, J = 7.2 Hz, ArCH2), 4.88 (2H, m, CH2O), 6.27 (1H, s, ArH-6), 6.99 (2H, s, 
ArH-3″,5″), 7.04 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.50 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.35 
(1H, s, ArH-3), 9.72 (1H, s, NH); MS m/z (%) 465.1 (M + Na, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
isopropylcarbamoyl-2-nitroaniline (11d)—The preparation is the same as that of 5a–c. 
Starting with carboxylic acid compound 11b (250 mg, 0.55 mmol) and isopropylamine (4 
drops, excess) to afford 220 mg of 11d: 81% yield; mp 180.0–181.6 °C; 1H NMR δ 1.27 
(6H, d, J = 6.4 Hz, 2 × CH3), 2.13 (6H, s, 2 × CH3), 2.64 (2H, t, J = 7.2 Hz, CH2CN), 2.90 
(2H, t, J = 7.2 Hz, ArCH2), 4.35 (1H, m, CH), 6.28 (1H, s, ArH-6), 7.03 (2H, s, ArH-3″,5″), 
7.06 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.51 (1H, d, J = 7.6 Hz, CONH), 7.53 (2H, d, J = 8.8 
Hz, ArH-3′,5′), 9.27 (1H, s, ArH-3), 9.76 (1H, s, NH); MS m/z (%) 498.2 (M + 1, 100).
4-Chloromethyl-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-
cyanophenyl)-2-nitroaniline (11e)—The preparation was the same as that of 4c. 
Starting with 11c (613 mg, 1.39 mmol) with 2,4,6-trichloro[1,3,5]triazine (306 mg, 1.66 
mmol) to afford 500 mg of pure 11e: 86% yield; yellow solid; mp 196–197 °C; 1H NMR δ 
2.13 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 2.88 (2H, t, J = 7.2 Hz, CH2Ar), 
4.77 (2H, s, CH2Cl), 6.25 (1H, s, ArH-6), 6.99 (2H, s, ArH-3″,5″), 7.07 (2H, d, J = 8.8 Hz, 
ArH-2′,6′), 7.52 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.40 (1H, s, ArH-3), 9.78 (1H, s, NH); MS 
m/z (%) 461.3 (M + 1, 100), 463.3 (M + 3, 10).
4-Amino-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-2-
nitroaniline (11f)—A mixture of 11b (200 mg, 0.44 mmol) and diphenylphosphorylazide 
(DPPA, 112 µL) in THF (8 mL) in the presence of Et3N (400 µL) was stirred at 25 °C for 3 
h. Water (5 mL) was added, and then the reaction mixture was refluxed for an additional 5 h. 
The solvent was diluted with H2O and extracted with EtOAc several times. The combined 
organic filtrate was washed with brine and dried over anhydrous Na2SO4. After removal of 
solvent, the residue was purified by flash chromatography (gradient elution, MeOH/
petroleum ether, 10 to 60%) to afford 78 mg of 11f: 42% yield; mp 211–212 °C; 1H NMR 
(DMSO-d6) δ 2.07 (6H, s, 2 × CH3), 3.79 (4H, t, J = 5.6 Hz, CH2CH2CN), 5.66 (2H, s, 
NH2) 6.06 (1H, s, ArH-6), 6.82 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.10 (2H, s, ArH-3″,5″), 
7.49 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.52 (1H, s, ArH-3), 8.84 (1H, s, NH); MS m/z (%) 
428.3 (M + 1, 100).
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5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
ethoxymethyl-2-nitroaniline (11m)—Compound 11e (238 mg, 0.52 mmol) in EtOH (25 
mL) was heated at 100 °C under microwave irradiation for 20 min. The precipitated solid 
was collected and dried to produce 203 mg of 11m: 84% yield; yellow solid; mp 136.3–
137.0 °C; 1H NMR δ 1.34 (3H, t, J = 6.8 Hz, CH3), 2.09 (6H, s, 2 × CH3), 2.63 (2H, t, J = 
6.8 Hz, CH2CN), 2.90 (2H, t, J = 6.8 Hz, ArCH2), 3.71 (2H, q, J = 6.8 Hz, OCH2), 4.71 (2H, 
s, ArCH2O), 6.28 (1H, s, ArH-6), 7.00 (2H, s, ArH-3″,5″), 7.06 (2H, d, J = 8.8 Hz, ArH-2′,
6′), 7.51 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.41 (1H, s, ArH-3), 9.73 (1H, s, NH); MS m/z (%) 
471.2 (M + 1, 100).
4-Bromo-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-2-
nitroaniline (11n) and a Byproduct without a 4-Substituent (11o)—A mixture of 
11f (27 mg, 0.06 mmol), aq HBr (105 µL, 40%), and aq NaNO3 (55 µL, 27%) in 0.5 mL of 
THF was stirred at 5 °C for 1 h, and then CuBr (16 mg, 0.11 mmol) and HBr (58 µL, 40%) 
were added successively while the mixture was being stirred at 5 °C for an additional 3 h. 
The solid was removed by filtration and washed with EtOAc several times. The organic 
phase was separated, and the water phase was extracted with EtOAc. The solvent of the 
combined organic phase was removed under reduced pressure, and the residue crude product 
was separated by a flash column chromatograph (gradual elution, CH2Cl2/petroleum ether, 0 
to 80%) to produce pure 11n (7 mg) and 11o (9 mg) in 23 and 35% yields, respectively. 11n: 
mp 180.0–182.0 °C; 1H NMR δ 2.10 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 
2.88 (2H, t, J = 7.2 Hz, ArCH2), 6.30 (1H, s, ArH-6), 6.98 (2H, s, ArH-3″,5″), 6.99 (2H, d, 
J = 8.8 Hz, ArH-3′,5′), 7.52 (2H, d, J = 8.8 Hz, ArH-2′,6′), 8.58 (1H, s, ArH-3), 9.63 (1H, 
s, NH); MS m/z (%) 513.5 (M + Na, 50), 515.1 (M + 2 + Na, 100). 11o: mp 171.3–
173.0 °C; 1H NMR δ 2.11 (6H, s, 2 × CH3), 2.64 (2H, t, J = 7.2 Hz, CH2CN), 2.90 (2H, t, J 
= 7.2 Hz, ArCH2), 6.30 (1H, dd, J = 9.2 Hz, J = 2.4 Hz, ArH-4), 6.75 (1H, d, J = 2.4 Hz, 
ArH-6), 6.98 (2H, s, ArH-3″,5″), 7.28 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.63 (2H, d, J = 8.8 
Hz, ArH-3′,5′), 8.20 (1H, d, J = 9.2 Hz, ArH-3), 9.76 (1H, s, NH); MS m/z (%) 413.2 (M 
+ 1, 100).
4-Chloro-5-[4″-(2-cyanoethyl)-N1-(4′-cyanophenyl)-2″,6″-dimethylphenoxy]-2-
nitroaniline (11p)—A mixture of 10b (166 mg, 0.50 mmol), 9a (90 mg, 0.60 mmol), and 
K2CO3 (138 mg, 1.0 mmol) in DMF (3 mL) was heated at 110 °C under microwave 
irradiation while the mixture was being stirred for 20 min. The reaction was monitored by 
TLC until it reached completion. The mixture was poured into ice-water, and the solid 
product was filtered. The product was purified by CombiFlash column chromatography 
(gradient elution, CH2Cl2/petroleum ether, 0 to 75%) to give 215 mg of 11p: 55% yield; 
orange solid; mp 178–180 °C; 1H NMR δ 2.12 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, 
CH2CN), 2.88 (2H, t, J = 7.2 Hz, ArCH2), 6.32 (1H, s, ArH-6), 6.99 (2H, s, ArH-3″,5″), 
7.04 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.52 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.41 (1H, s, 
ArH-3), 9.62 (1H, s, NH); MS m/z (%) 447.3 (M + 1, 50), 449.3 (M + 3, 24), 469.3 (M + 
Na, 100).
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Catalytic Hydrogenation To Prepare 4-Substituted 1,5-Diarylbenzene-1,2-diamines (6 
series)
A 4-substituted 1,5-diaryl-4-nitrobenzene (5 or 11) in EtOH or EtOAc (∼20 mL) in the 
presence of Pd-C (5–10%, excess) was shaken with H2 under a pressure of 50–55 psi, 
monitored by TLC for a period of 4–10 h. The solid catalyst was removed by filtration and 
washed with EtOAc. The solvent of the combined filtrate was removed under reduced 
pressure, and the residue was purified by flash column chromatography (gradual elution, 
MeOH/CH2Cl2, 0 to 5%) to produce corresponding pure 6 series compounds.
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-(N,N-
dimethylcarbamoyl)benzene-1,2-diamine (6a)—Starting with 5a (227 mg, 0.47 
mmol) to afford 156 mg of 6a: 78% yield; white solid; mp 232.6–233.3 °C; 1H NMR δ 2.10 
(6H, s, 2 × CH3), 2.60 (2H, t, J = 7.2 Hz, CH2CN), 2.86 (2H, t, J = 7.2 Hz, ArCH2), 3.10 
(3H, s, CH3), 3.16 (3H, s, CH3), 3.60 (2H, s, NH2), 5.77 (1H, s, NH), 6.12 (1H, s, ArH-6), 
6.60 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.84 (1H, s, ArH-3), 6.92 (2H, s, ArH-3″,5″), 7.39 
(2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 454.4 (M + 1, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-(N-
ethylcarbamoyl)benzene-1,2-diamine (6b)—Starting with 5b (120 mg, 0.25 mmol) to 
afford 68 mg of 6b: 60% yield; white solid; mp 192.1–193.1 °C; 1H NMR δ 1.24 (3H, t, J = 
7.2 Hz, CH3), 2.13 (6H, s, 2 × CH3), 2.60 (2H, t, J = 7.2 Hz, CH2CN), 2.89 (2H, t, J = 7.2 
Hz, ArCH2), 3.55 (2H, q, J = 7.2 Hz, NHCH2), 5.88 (1H, s, NH), 6.21 (1H, s, ArH-6), 6.70 
(2H, d, J = 8.8 Hz, ArH-2′,6′), 6.84 (1H, s, ArH-3), 7.00 (2H, s, ArH-3″,5″), 7.41 (2H, d, J 
= 8.8 Hz, ArH-3′,5′), 7.82 (1H, s, ArH-3), 7.98 (1H, br, CONH); MS m/z (%) 454.4 (M + 1, 
100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-(N-
cyclopropylcarbamoyl)benzene-1,2-diamine (6c)—Starting with 5c (150 mg, 0.30 
mmol) to afford 115 mg of 6c: 82% yield; white solid; mp 221.0–222.7 °C; 1H NMR δ 1.42 
(4H, 2 × CH2), 2.08 (6H, s, 2 × CH3), 2.17 (1H, m, CH), 2.60 (2H, t, J = 7.2 Hz, CH2CN), 
2.86 (2H, t, J = 7.2 Hz, ArCH2), 4.66 (2H, s, NH2), 5.53 (1H, s, NH), 6.02 (1H, s, ArH-6), 
6.54 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.91 (2H, s, ArH-3″,5″), 6.97 (1H, s, ArH-3), 7.39 
(2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 466.4 (M + 1, 88), 409.3 (M - 56, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
(isopropylcarbamoyl)benzene-1,2-diamine (6d)—Starting with 11d (200 mg, 0.40) 
in EtOAc (25 mL) for 4 h to afford 150 mg of 6d: 80% yield; mp 216.0–218.0 °C; 1H NMR 
δ 1.27 (6H, d, J = 6.8 Hz, 2 × CH3), 2.16 (6H, s, 2 × ArCH3), 2.64 (2H, t, J = 7.2 Hz, 
CH2CN), 2.90 (2H, t, J = 7.2 Hz, ArCH2), 4.35 (1H, m, CH), 5.85 (1H, s, NH), 6.20 (1H, s, 
ArH-6), 6.66 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.93 (2H, s, ArH-3″,5″), 7.42 (2H, d, J = 8.8 
Hz, ArH-3′,5′), 7.80 (1H, s, ArH-3), 7.85 (1H, d, J = 6.8 Hz, NH); MS m/z (%) 468.3 (M 
+ 1, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-(N,N-
dimethylamino)methylbenzene-1,2-diamine (6e)—Starting with 5e (100 mg, 0.21 
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mmol) to afford 70 mg of 6e: 75% yield; white solid; mp 142.4–143.9 °C; 1H NMR δ 2. 08 
(6H, s, 2 × CH3), 2.39 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 2.87 (2H, t, J = 
7.2 Hz, ArCH2), 3.67 (2H, s, ArCH2), 5.51 (1H, s, NH), 6.02 (1H, s, ArH-6), 6.54 (2H, d, J 
= 8.8 Hz, ArH-2′,6′), 6.94 (2H, s, ArH-3″,5″), 7.01 (1H, s, ArH-3), 7.40 (2H, d, J = 9.2 Hz, 
ArH-3′,5′); MS m/z (%) 454.2 (M + 1, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
(cyclopropylamino)methylbenzene-1,2-diamine (6f)—Starting with 5f (110 mg, 0.23 
mmol) to afford 60 mg of 6f: 58% yield; white solid; mp 106.2–108.0 °C; 1H NMR δ 0.48 
(4H, m, 2 × CH2), 2.10 (6H, s, 2 × CH3), 2.23 (1H, m, CH), 2.14 (2H, t, J = 7.0 Hz, 
CH2CN), 2.88 (2H, t, J = 7.0 Hz, ArCH2), 3.53 (2H, s, NH2), 3.99 (2H, s, ArCH2), 5.51 (1H, 
s, NH), 6.02 (1H, s, ArH-6), 6.54 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.86 (1H, s, ArH-3), 6.94 
(2H, s, ArH-3″,5″), 7.40 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 354.1 (M - 98, 100), 
474.0 (M + Na, 10).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-(4-
methylpiperazin-1-yl)methylbenzene-1,2-diamine (6g)—Starting with 5g (110 mg, 
0.21 mmol) to afford 30 mg of 6g: 29% yield; white solid; mp 90.9–92.6 °C; 1H NMR δ 
2.15 (6H, s, 2 × CH3), 2.33 (3H, s, NCH3), 2.60 (10H, 5 × CH2), 2.87 (2H, t, J = 7.2 Hz, 
ArCH2), 3.74 (2H, s, CH2N), 5.52 (1H, s, NH), 6.02 (1H, s, ArH-6), 6.55 (2H, d, J = 8.8 Hz, 
ArH-2′,6′), 6.91 (2H, s, ArH-3″,5″), 6.97 (1H, s, ArH-3), 7.40 (2H, d, J = 8.8 Hz, ArH-3′,
5′); MS m/z (%) 495.6 (M + 1, 4.9), 395 (M - 99, 100).
4-Acetoxymethyl-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-
cyanophenyl)benzene-1,2-diamine (6h)—Starting with 5h (80 mg, 0.17 mmol) to 
afford 30 mg of 6h: 40% yield; white solid; mp 164.1–165.7 °C; 1H NMR (DMSO-d6) δ 
2.04 (6H, s, 2 × CH3), 2.09 (3H, s, COCH3), 2.78 (4H, s, 2 × CH2), 4.58 (2H, s, NH2), 5.19 
(2H, s, CH2O), 5.90 (1H, s, NH), 6.54 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.87 (1H, s, ArH-6), 
7.04 (2H, s, ArH-3″,5″), 7.45 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.08 (1H, s, ArH-3); MS m/z 
(%) 455.3 (M + 1, 17), 395.2 (M - 59, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
[(cyclopropylcarbonyl)oxy]methylbenzene-1,2-diamine (6i)—Starting with 5i (180 
mg, 0.35 mmol) to afford 35 mg of 6i: 21% yield; white solid; mp 188.2–189.6 °C; 1H NMR 
δ 0.90 (2H, m, CH2), 1.06 (2H, m, CH2), 1.70 (1H, m, CH), 2.10 (6H, s, 2 × CH3), 2.61 
(2H, t, J = 6.8 Hz, CH2CN), 2.87 (2H, t, J = 6.8 Hz, ArCH2), 3.48 (2H, s, NH2), 5.31 (2H, s, 
CH2O), 5.56 (1H, s, NH), 6.06 (1H, s, ArH-6), 6.58 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.92 
(3H, s, ArH-3,3″,5″), 7.41 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 481.5 (M + 1, 33), 
395.2 (M - 85, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4″-cyanophenyl)-4-(N-
methyl carbamate)methyl-2-nitroaniline (6j)—Starting with 5j (150 mg, 0.30 mmol) 
to afford 67 mg of 6j: 48% yield; white solid; mp 203–204 °C; 1H NMR δ 2.09 (6H, s, 2 × 
CH3), 2.61 (2H, t, J = 6.8 Hz, CH2CN), 2.86 (5H, m, ArCH2 and NCH3), 3.48 (2H, s, NH2), 
4.71 (1H, s, CONH), 5.31 (2H, s, CH2O), 5.56 (1H, s, NH), 6.05 (1H, s, ArH-6), 6.56 (2H, 
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d, J = 8.8 Hz, ArH-2′,6′), 6.92 (3H, s, ArH-3″,5″), 6.93 (1H, s, ArH-3) 7.40 (2H, d, J = 8.8 
Hz, ArH-3′,5′); MS m/z (%) 470.1 (M + 1, 22), 395.2 (M - 74, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
methoxymethylbenzene-1,2-diamine (6k)—Starting with 5k (150 mg, 0.33 mmol) to 
afford 110 mg of 6k: 79% yield; white solid; mp 103.6–104.8 °C; 1H NMR δ 2.09 (6H, s, 2 
× CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 2.87 (2H, t, J = 7.2 Hz, ArCH2), 3.52 (3H, s, 
OCH3), 4.67 (2H, s, CH2O), 5.56 (1H, s, NH), 6.03 (1H, s, ArH-6), 6.55 (2H, d, J = 8.8 Hz, 
ArH-2′,6′), 6.92 (2H, s, ArH-3″,5″), 6.99 (1H, s, ArH-3), 7.39 (2H, d, J = 8.8 Hz, ArH-3′,
5′); MS m/z (%) 427.3 (M + 1, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-cyanophenyl)-4-
(ethoxymethyl)benzene-1,2-diamine (6m)—Starting with 11e (180 mg, 0.38 mmol) in 
EtOAc (20 mL) for 4 h to afford 97 mg of 6m: 58% yield; white solid; mp 135.9–
137.2 °C; 1H NMR δ 1.32 (3H, t, J = 7.2 Hz, CH3), 2.09 (6H, s, 2 × CH3), 2.61 (2H, t, J = 
7.2 Hz, CH2CN), 2.87 (2H, t, J = 7.2 Hz, ArCH2), 3.70 (2H, q, J = 7.2 Hz, OCH2), 4.71 (2H, 
s, ArCH2O), 5.54 (1H, s, NH), 6.02 (1H, s, ArH-6), 6.54 (2H, d, J = 8.8 Hz, ArH-2′,6′), 
6.92 (2H, s, ArH-3″,5″), 7.00 (1H, s, ArH-3), 7.39 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z 
(%) 441.4 (M + 1, 100).
4-Bromo-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-
cyanophenyl)benzene-1,2-diamine (6n) and 5-[4″-(2-Cyanoethyl)-2″,6″-
dimethylphenoxy]-N1-(4′-cyanophenyl)benzene-1,2-diamine (6o)—The mixture 
of 11n and 11o (60 mg), Fe powder (22 mg, 0.39 mmol), and NH4Cl (70 mg, 1.3 mmol) in a 
mixed solvent of THF, MeOH, and H2O [24 mL, 1:1:1 (v/v/v)] was heated to reflux for 3 h. 
The solid was filtered out and washed with EtOAc. The filtrate was extracted with EtOAc 
several times. After removal of organic solvent under reduced pressure, the residue was 
separated by preparative HPLC using a C18 column chromatograph (gradient elution, 
methanol/water, 55 to 75%) to produce pure 6n (17 mg) and 6o (18 mg). 6n: white solid; mp 
199.5–201.3 °C; 1H NMR δ 2.12 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, CH2CN), 2.87 
(2H, t, J = 7.2 Hz, ArCH2), 3.54 (2H, s, NH2), 5.65 (1H, s, NH), 6.12 (1H, s, ArH-6), 6.56 
(2H, d, J = 8.4 Hz, ArH-2′,6′), 6.93 (2H, s, ArH-3″,5″), 7.12 (1H, s, ArH-3), 7.42 (2H, d, J 
= 8.4 Hz, ArH-3′,5′); MS m/z (%) 461.0 (M + 1, 100), 463.0 (M + 3, 100). 6o: white solid; 
mp 174.5–176.3 °C; 1H NMR δ 2.12 (6H, s, 2 × CH3), 2.63 (2H, t, J = 7.2 Hz, CH2CN), 
2.89 (2H, t, J = 7.2 Hz, ArCH2), 5.65 (1H, s, NH), 6.53 (1H, dd, J = 8.8 Hz, J = 2.8 Hz, 
ArH-4), 6.56 (1H, d, J = 2.8 Hz, ArH-6), 6.69 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.73 (1H, d, J 
= 9.2 Hz, ArH-3), 6.93 (2H, s, ArH-3″,5″), 7.46 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z 
(%) 383.3 (M + 1, 41.4), 209.0 (M - 173, 100).
4-Chloro-5-[4″-(2-cyanoethyl)-2″,6″-dimethylphenoxy]-N1-(4′-
cyanophenyl)benzene-1,2-diamine (6p)—Reduction followed the same preparation 
that was used for 6n. The mixture of 11p (115 mg, 0.26 mmol), iron powder (43 mg, 0.77 
mmol), and NH4Cl (139 mg, 2.60 mmol) in a mixed solvent of THF, MeOH, and H2O [24 
mL, 1:1:1 (v/v/v)] was heated to reflux for 3 h. After removal of the inorganic solid and 
organic solvent, the crude product was separated by preparative HPLC using a C18 column 
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chromatograph (gradient elution, methanol/water, 55 to 75%) to afford 70 mg of 6p: white 
solid; mp 182.1–183.6 °C; 1H NMR δ 2.12 (6H, s, 2 × CH3), 2.61 (2H, t, J = 7.2 Hz, 
CH2CN), 2.87 (2H, t, J = 7.2 Hz, ArCH2), 3.55 (2H, s, NH2), 5.50 (1H, s, NH), 6.14 (1H, s, 
ArH-6), 6.55 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.92 (2H, s, ArH-3″,5″), 6.95 (1H, s, ArH-3), 
7.41 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 417.2 (M + 1, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethoxyphenoxy]-N1-(4′-cyanophenyl)-4-
methoxycarbonyl-2-nitroaniline (13a)—The preparation was the same as that of 11a. 
Starting with 10a (1 g, 3.00 mmol) and 9b (750 mg, 3.60 mmol) in DMF (20 mL) in the 
presence of K2CO3 (828 mg, 6.00 mmol) to afford 1.2 g of 13a: 80% yield; yellow solid; mp 
172.3–174.0 °C; 1H NMR δ 2.64 (2H, t, J = 7.2 Hz, CH2CN), 2.92 (2H, t, J = 7.2 Hz, 
ArCH2), 3.80 (6H, s, 2 × OCH3), 3.94 (3H, d, J = 4.8 Hz, OCH3), 6.47 (1H, s, ArH-6), 6.51 
(2H, s, ArH-3″,5″), 7.15 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.54 (2H, d, J = 8.8 Hz, ArH-3′,
5′), 8.98 (1H, s, ArH-3), 9.80 (1H, s, NH); MS m/z (%) 503.1 (M + 1, 100).
5-[2″-Bromo-4″-(2-cyanoethyl)-6″-methoxyphenoxy]-N1-(4′-cya-nophenyl)-4-
methoxycarbonyl-2-nitroaniline (14a)—The preparation was the same as that of 11a. 
Starting with 10a (455 mg, 1.37 mmol), 9c (264 mg, 1.15 mmol), and K2CO3 (414 mg, 3 
mmol) in DMF (10 mL) to afford 340 mg of 14a: 60% yield; yellow solid; mp 174.2–
175.2 °C; 1H NMR δ 2.64 (2H, t, J = 6.8 Hz, CH2CN), 2.92 (2H, t, J = 6.8 Hz, ArCH2), 
3.80 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6.35 (1H, s, ArH-6), 6.89 (1H, d, J = 2.4 Hz, 
ArH-5″), 7.10 (1H, d, J = 2.4 Hz, ArH-3″), 7.20 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.57 (2H, 
d, J = 8.8 Hz, ArH-3′,5′), 9.00 (1H, s, ArH-3), 9.81 (1H, s, NH); MS m/z (%) 551.0 (M + 1, 
34), 553.0 (M + 3, 36), 440.2 (M - 110, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethoxyphenoxy]-N1-(4′-cyanophenyl)-4-
methylcarbamoyl-2-nitroaniline (13b)—A mixture of 13a (100 mg, 0.20 mmol) and an 
aqueous CH3NH2 solution (25–30%, 1 mL, excess) in THF (3 mL) was stirred vigorously at 
40 °C for 4 h. The mixture was poured into ice-water, and the pH was adjusted to 4 with aq 
HCl (5%). The precipitated yellow solid was collected and purified by CombiFlash column 
chromatography (gradient elution, EtOAc/petroleum ether, 60 to 100%) to produce 57 mg of 
13b: 57% yield; yellow solid; mp 202–203 °C; 1H NMR δ 2.70 (2H, t, J = 7.2 Hz, CH2CN), 
2.98 (2H, t, J = 7.2 Hz, ArCH2), 3.06 (3H, d, J = 4.8 Hz, NCH3), 3.84 (6H, s, 2 × OCH3), 
6.51 (1H, s, ArH-6), 6.56 (2H, s, ArH-3″,5″), 7.17 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.56 
(2H, d, J = 8.8 Hz, ArH-3′,5′), 7.69 (1H, d, J = 4.8 Hz, CONH), 9.19 (1H, s, ArH-3), 9.76 
(1H, s, NH); MS m/z (%) 502.1 (M + 1, 100).
5-[2″-Bromo-4″-(2-cyanoethyl)-6″-methoxyphenoxy]-N1-(4′-cya-nophenyl)-4-
methylcarbamoyl-2-nitroaniline (14b)—The preparation was the same as that of 13b. 
Starting with 14a (340 mg, 0.62 mmol) and an aqueous CH3NH2 solution (25–30%, excess) 
to afford 105 mg of 14b: 31% yield; yellow solid; mp 225–227 °C; 1H NMR δ 2.68 (2H, t, J 
= 6.8 Hz, CH2CN), 2.95 (2H, t, J = 6.8 Hz, ArCH2), 3.06 (3H, d, J = 4.8 Hz, NCH3), 3.83 
(3H, s, OCH3), 6.38 (1H, s, ArH-6), 6.88 (1H, d, J = 2.0 Hz, ArH-5″), 7.13 (1H, d, J = 2.0 
Hz, ArH-3″), 7.18 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.47 (1H, d, J = 4.8 Hz, CONH), 7.56 
Liu et al. Page 22
J Med Chem. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(2H, d, J = 8.8 Hz, ArH-3′,5′), 9.21 (1H, s, ArH-3), 9.73 (1H, s, NH); MS m/z (%) 550.0 
(M + 1, 78), 552.0 (M + 3, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethoxyphenoxy]-N1-(4′-cyanophenyl)-4-
methoxycarbonylbenzene-1,2-diamine (13c)—The catalytic hydrogenation was the 
same as the preparation of 6a. Starting with 13a (200 mg, 0.40 mmol) in EtOAc (20 mL) for 
4 h to produce 140 mg of 13c: 74% yield; white solid; mp 176.6–178.3 °C; 1H NMR δ 2.60 
(2H, t, J = 7.2 Hz, CH2CN), 2.90 (2H, t, J = 7.2 Hz, ArCH2), 3.75 (6H, s, 2 × OCH3), 3.89 
(3H, s, OCH3), 5.87 (1H, s, NH), 6.47 (3H, s, ArH-6,3′,5′), 6.73 (2H, d, J = 8.8 Hz, ArH-2′,
6′), 7.40 (1H, s, ArH-3), 7.41 (2H, d, J = 8.8 Hz, ArH-3′,5′); MS m/z (%) 473.2 (M + 1, 
33.6), 441.3 (M - 31, 100).
5-[4″-(2-Cyanoethyl)-2″,6″-dimethoxyphenoxy]-N1-(4′-cyanophenyl)-4-
methylcarbamoylbenzene-1,2-diamine (13d)—The catalytic hydrogenation was the 
same as the preparation of 6a. Starting with 13b (170 mg, 0.34 mmol) to afford 100 mg of 
13d: 63% yield; white solid; mp 240.3–241.9 °C; 1H NMR δ 2.67 (2H, t, J = 7.2 Hz, 
CH2CN), 2.95 (2H, t, J = 7.2 Hz, ArCH2), 3.02 (3H, d, J = 4.4 Hz, NCH3), 3.49 (2H, s, 
NH2), 3.80 (6H, s, 2 × OCH3), 5.89 (1H, s, NH), 6.45 (1H, s, ArH-6), 6.52 (2H, s, ArH-3″,
5″), 6.74 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.42 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.64 (1H, s, 
ArH-3), 8.00 (1H, d, J = 4.4 Hz, CONH); MS m/z (%) 472.2 (M + 1, 100).
5-[2″-Bromo-4″-(2-cyanoethyl)-6″-methoxyphenoxy]-N1-(4′-cya-nophenyl)-4-
methoxycarbonylbenzene-1,2-diamine (14c)—Reduction with Fe/NH4Cl was the 
same as that used in the preparation of 6p. Starting with 14a (crude, 250 mg, 0.48 mmol), 
iron (269 mg, 4.8 mmol), and NH4Cl (257 mg, 4.8 mmol) to afford 70 mg of 14c: white 
solid; mp 196.6–197.1 °C; 1H NMR δ 2.64 (2H, t, J = 7.2 Hz, CH2CN), 2.91 (2H, t, J = 7.2 
Hz, ArCH2), 3.44 (2H, s, NH2), 3.77 (3H, s, OCH3), 3.92 (3H, s, 2 × CH3), 5.87 (1H, s, 
NH), 6.38 (1H, s, ArH-6), 6.76 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.81 (1H, d, J = 2 Hz, 
ArH-5″), 6.95 (1H, s, ArH-3), 7.06 (1H, d, J = 2 Hz, ArH-3″), 7.43 (2H, d, J = 8.8 Hz, 
ArH-3’,5’), 7.45 (1H, s, ArH-3); MS m/z (%) 521.3 (M + 1, 100), 523.2 (M + 3, 83).
5-[2″-Bromo-4″-(2-cyanoethyl)-6″-methoxyphenoxy]-N1-(4′-cya-nophenyl)-4-
methylcarbamoylbenzene-1,2-diamine (14d)—The preparation was same as that of 
6p. Starting with 14b (100 mg, 0.18 mmol), iron (30 mg, 0.54 mmol), and NH4Cl (95 mg, 
1.82 mmol) to give 60 mg of 14d: 64% yield; white solid; mp 228–230 °C; 1H NMR δ 2.67 
(2H, t, J = 6.8 Hz, CH2CN), 2.94 (2H, t, J = 6.8 Hz, ArCH2), 3.55 (2H, br, NH2), 3.06 (3H, 
d, J = 4.4 Hz, CH3), 3.79 (3H, s, OCH3), 5.90 (1H, s, NH), 6.33 (1H, s, ArH-6), 6.74 (2H, d, 
J = 8.4 Hz, ArH-2′,6′), 6.84 (1H, s, ArH-5″), 7.10 (1H, s, ArH-3″), 7.43 (2H, d, J = 8.4 Hz, 
ArH-3’,5’), 7.69 (1H, s, ArH-3), 7.76 (1H, d, J = 4.4 Hz, NH); MS m/z (%) 520.2 (M + 1, 
84), 522.2 (M + 3, 100).
Bioassays
Assay for Measuring the Inhibitory Activity of Compounds on HIV-1 Infection 
of TZM-bl Cells—Inhibition of HIV-1 infection was measured as a reduction in the level of 
luciferase gene expression after a single round of virus infection of TZM-bl cells as 
Liu et al. Page 23
J Med Chem. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
described previously. Briefly, 800 TCID50 of virus (NL4-3 or drug-resistant variants) was 
used to infect TZM-bl cells in the presence of various concentrations of compounds. One 
day after infection, the culture medium was removed from each well, and 100 µL of Bright 
Glo reagent (Promega, San Luis Obispo, CA) was added to the cells to measure 
luminescence using a Victor 2 luminometer. The effective concentration (EC50) against 
HIV-1 strains was defined as the concentration that caused a 50% decrease in luciferase 
activity (relative light units) compared to that of virus control wells.
HIV-1 Infection Assay Using MT-2 Cells—The inhibitory activity of compounds 
against infection by HIV-1 IIIB and its variant A17, which is resistant to multiple NNRTIs, 
was determined as previously described.30 Briefly, MT-2 cells (104 per well) were infected 
with an HIV-1 strain (100 TCID50) in 200 µL of RPMI 1640 containing 10% FBS in the 
presence or absence of a test compound at graded concentrations overnight. Then the culture 
supernatants were removed, and fresh media containing no test compounds were added. On 
the fourth day postinfection, 100 µL of culture supernatants was collected from each well, 
mixed with equal volumes of 5% Triton X-100, and assayed for p24 antigen, which was 
quantitated by an enzyme-linked immunosorbent assay, and the percentage of inhibition of 
p24 production was calculated as previously described. The effective concentrations for 50% 
inhibition (EC50) were calculated using CalcuSyn.
Cytotoxicity Assay—A CytoTox-Glo cytotoxicity assay (Promega) was used to 
determine the cytotoxicity of the synthesized compounds. Parallel to the antiviral assays, 
TZM-bl cells were cultured in the presence of various concentrations of the compounds for 1 
day. The percent of viable cells was determined by following the protocol provided by the 
manufacturer. The 50% cytotoxic concentration (CC50) was defined as the concentration that 
caused a 50% reduction in cell viability.
Molecular Modeling Studies
Molecules 6a [X = Me/Me and R = −(C═O)NMe2], 14d [X = OMe/Br; R = − 
(C═O)OCH3], and 1b were sketched in MOE (Molecular Operating Environment, version 
2011.10, Chemical Computing Group, Toronto, Canada). Conformational searches were 
conducted using MOE. The default parameters were applied (lowModeMD, rejection limit 
of 100, iteration limit of 10000, RMS gradient of 0.005, MM iteration limit of 500, 
conformational limit of 10000). This process resulted in 155 conformers for 6a, 440 
conformers for 14d, and 35 conformers for 1b. The crystal structures of wild-type and 
E138K mutant HIV-1 RT in complex with 1b (PDB entry 3MEC) and nevirapine (PDB entry 
2HNY), respectively, were downloaded from the RCSB Protein Data Bank for use in this 
modeling study. The docking tool in MOE 2011.10 was used to conduct the docking 
simulations. The X-ray crystal structures of 3MEC and 2HNY were adopted to represent 
both wild-type and mutant structures. The pocket atoms as well as residue 138 were 
included in the binding site model. Default docking parameters were applied. The three 
conformational databases for 6a, 14d, and 1b were used in the docking simulations. Poses 
were visually analyzed to ensure that the hydrogen bonds between the drug molecules and 
K101 were preserved for final analysis. The docking results of 14d are shown in Figures S1 
and S2 of the Supporting Information.
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Aqueous Solubility Determination
Solubility was measured separately at pH 7.4 and 2.0 by using an HPLC-UV method. Test 
compounds were initially dissolved in DMSO at a concentration of 10 mg/mL. Ten 
microliters of this stock solution was spiked into either pH 7.4 phosphate buffer (1.0 mL) or 
0.01 M HCl (approximately pH 2.0, 1.0 mL) with the final DMSO concentration being 1%. 
The mixture was stirred for 4 h at room temperature and then concentrated at 10000 rpm for 
5 min. The saturated supernatants were transferred to other vials for analysis by HPLC-UV 
and detected at 254 nm. Each sample was analyzed in triplicate. For quantification, a model 
1200 HPLC-UV (Agilent) system was used with an Agilent Eclipse XDB-C18 column (150 
mm × 4.6 mm, 5 µm) and gradient elution of methanol (MeOH) in water, starting with 60% 
MeOH, which was linearly increased to 80% over 10 min and then slowly increased to 90% 
over 15 min. The flow rate was 1.0 mL/min, and the injection volume was 15 µL. The 
aqueous concentration was determined by comparison of the peak area of the saturated 
solution with a standard curve plotted as peak area versus known concentrations, which were 
prepared by solutions of the test compound in acetonitrile (ACN) at 50, 25, 12.5, 3.13, 0.78, 
and 0.20 µg/mL.
Log P Measurement
Using the same DMSO stock solution (10 mg/mL) described above, 10 µL of this solution 
was added to n-octane (0.6 mL) and water (0.6 mL). The mixture was stirred at rt for 24 h 
and then left to stand overnight. Each solution (∼0.2 mL) from two phases was transferred 
into other vials for HPLC analysis. The instrument and conditions were the same as those 
for solubility determination. The log P value was calculated by the peak area ratios in n-
octane and in water [log P = log(Soct/Swater)].
Microsomal Stability Assay
DMSO stock solutions of test compounds (1–2 mg) were prepared at a concentration of 0.5 
mM and stored at 4 °C. Before the assay, a dilute solution of a test compound was prepared 
by adding 50 µL of each DMSO stock solution to 200 µL of acetonitrile to make 0.1 mM 
solutions in a mixture of solvents, DMSO and acetonitrile (1:4, v/v). Human liver 
miscrosomes (protein content of 20 mg/mL, 0.5 mL), 0.1 M potassium phosphate buffer (pH 
7.4), and 0.5 M MgCl2 were mixed, and a testing compound was added to the solution. A 
240 µL volume of incubation solution was transferred to time 0, 5, 15, 30, and 45 min vials 
(each in duplicate wells) for warming at 37 °C for more than 5 min. The NADPH 
regenerating agent (5 mM in buffer, 60 µL) was added to each vial, except the 0 min vial, to 
initiate the reaction. The incubation volume in each vial was 300 µL. The final 
concentrations of components in the incubation were 1 µM test compound, 0.1 mg/mL 
human liver microsomes, 5 mM MgCl2, and 1.0 mM NADPH with 0.1 M potassium 
phosphate buffer (pH 7.4). The reaction temperature was 37 °C, and the reaction was 
quenched by adding 600 µL of icecold ACN to stop the reaction at 5, 15, 30, and 45 min. 
Samples at the 0 min time point were prepared by adding 600 µL of ice-cold ACN first, 
followed by 60 µL of NADPH. Incubations of all samples were conducted in duplicate. 
After quenching, all samples were centrifuged at 12000 rpm for 5 min at 4 °C. A 150 µL 
volume of supernatant was collected carefully for further LC-MS analysis. Peaks of test 
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compounds at different time points were converted to percentage of remaining, and the peak 
values at initial time (0 min) served as 100%. The slope of the linear regression from the log 
percentage remaining versus incubation time (−k) was used to calculate the in vitro half-life 
(t1/2) as in vitro t1/2 = 0.693/k, regarded as first-order kinetics. LC-MS analysis was 
conducted on an AB MDS Sciex API-3000 mass spectrometer with an electrospray 
ionization source (ESI). An Agilent Eclipse XDB-C18 column (4.6 mm × 150 mm, 5 µm) 
was used for HPLC, and 10 µL of the supernatant were directly injected by an autosampler. 
The elution condition was ACN (80%) in water (20% with 0.1% HCOOH) at a flow rate 0.5 
mL/min. Electrospray ionization was operated in the positive and negative mode. The 
signals were detected with ESI (−) or (+) by using multiple-reaction monitoring (MRM).
Determination of Predictive Physicochemical Properties
Ligand efficiency (LE) values were calculated by normalizing the binding free energy of a 
ligand for the number of heavy atoms, as shown in the formula −ΔG/HA(non-hydrogen atom). 
Free binding energy calculation was carried out as ΔG = −RT ln Kd, presuming EC50 ≈ Kd, a 
temperature of 310 K, and given in kilocalories per heavy atom (non-hydrogen atom). The 
pEC50 values, negative logarithm of the molar effective concentration of a compound that 
causes 50% inhibition of wild-type virus, were converted from experimental data. Lipophilic 
ligand efficiency (LLE) was calculated by the formula pEC50 - clog D, in which clog D 
values were calculated using ACD software. LELP was defined as the ratio of clog D and 
LE. The topological polar surface area (t-PSA) was calculated by using ChemDraw Ultra 
12.0.
X-ray Structure Deposition
The wild-type X-ray structure was deposited in the Protein Data Bank with a resolution of 
2.3 Å and the mutant structure 2HNY 3D with 2.5 Å.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
CC50 concentration that causes cytotoxicity to 50% of cells
DAAN diarylaniline
DAPA diarylpyridiamine
DAPY diary-lpyrimidine
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EC50 effective concentration that causes 50% inhibition of viral infection
HAART highly active antiretroviral therapy
HLM human liver microsome
LE ligand efficiency
LELP ligand efficiency-dependent lipophilicity
LLE lipophilic ligand efficiency
NNRTIs non-nucleoside reverse transcriptase inhibitors
SAR structure–activity relationship
SPR structure–property relationship
t-PSA topological polar surface area
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Figure 1. 
New-generation HIV-1 NNRTI drugs approved by the U.S. FDA.
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Figure 2. 
Prior leads 2 and 3, known SARs, and the current lead optimization strategy.
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Figure 3. 
Predicted binding modes of 6a (green sticks) and ligand 1b (gray sticks) with the HIV-1 RT 
wild-type crystal structure (3MEC) (top) and with the E138K mutant crystal structure 
(2HNY) (bottom), respectively, and overlapped. Both molecules 1b and 6a form two 
characteristic hydrogen bonds with K101 in both situations. Surrounding key amino acid 
side chains are shown in gray ball-and-stick format and labeled. Hydrogen bonds are shown 
as yellow dashed lines, and the distance between ligands and protein is <3 Å.
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Figure 4. 
Predicted and overlapped binding modes of 14d (green sticks) and 13d (red sticks) with the 
HIV-1 RT wild-type crystal structure (3MEC). The key amino acid side chains surrounding 
the C-ring are shown in gray stick format and labeled. The distance between ligands and 
protein is <3 Å.
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Scheme 1a
a(i) THF/MeOH, aq NaOH, rt, 10 h; (ii) (a) SOCl2, reflux, 4 h; (b) amine, THF, 0 °C, 0.5 h; 
(iii) LiBH4, THF/MeOH, 0 °C, 7 h; (iv) 2,4,6-trichloro[1,3,5]triazine, DMF/CH2Cl2, rt, 4 h; 
(v) amine, THF, 0 °C, for 5e–g; (vi) Ac2O, NaOH(s), 100 °C, microwave, 5 min for 5h; (vii) 
acylchloride, CH2Cl2/Py, for 5i and 5j; (viii) MeOH, BiCl3, in CH2Cl2, rt, 4 h, for 5k; (ix) 
H2/Pd-C, in EtOH or EtOAc.
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Scheme 2a
a(i) BnCl, K2CO3 or Et3N, in CH3CN, reflux, 3 h; (ii) (EtO)2PCO-(CH2CN), t-BuOK/THF, 
0 °C, 1 h; (iii) H2/Pd-C in EtOAc or EtOH.
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Scheme 3a
a(i) Cs2CO3/DMF, 80 °C, microwave, 20 min; (ii) K2CO3/DMF, 110 °C, heating for 4 h or 
microwave, 20 min; (iii) aq NaOH, THF/MeOH, rt, 8 h; (iv) LiBH4, THF/MeOH, 0 °C, 7 h; 
(v) (a) SOCl2, reflux, 3 h; (b) amine/THF, 0 °C, 0.5–1 h; (vi) (a) DPPA/Et3N/THF, rt, 3 h; 
(b) H2O, reflux, 3 h; (vii) (a) HBr/NaNO3/H2O, 5 °C, 1 h; (b) CuBr/HBr, 5 °C, 3 h; (viii) 
2,4,6-trichloro[1,3,5]triazine, DMF, CH2Cl2, rt, 4 h; (ix) EtOH, microwave at 100 °C, 20 
min; (x) H2/Pd-C in EtOAc, 2–3 h, rt; (xi) Fe/NH4Cl, THF/MeOH/H2O, reflux, 3 h.
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Scheme 4a
a(i) K2CO3/DMF, 120 °C, 4 h; (ii) aq CH3NH2/THF, 40 °C, 4 h; (iii) H2/Pd-C in EtOAc for 
13; (iv) Fe/NH4Cl, THF/MeOH/H2O, reflux, for 14.
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